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The main goal of this dissertation is to study the hypothesis of an acquisition in the 
biotechnology industry, between Amgen (acquirer) and Incyte (target). Amgen is a U.S.-based 
biotechnology company currently facing a decrease in sales, mainly due to an increase in the 
market share of generic drugs and the rise of biosimilar products. To offset the poor 
performance, it is looking for an acquisition in its industry, for which Incyte could be a suitable 
target. Incyte belongs to the U.S.-biotechnology industry, and although it has a shy presence in 
the market with only two released drugs, its revenues are expected to increase significantly in 
the near future. The combination of these companies would allow knowledge transfer about 
research and development process of new drugs, a stronger position in Europe, and a higher 
investment power to apply in R&D. The combined company would be able to decrease the 
number of employees due to duplication of jobs and decrease the cost of sales, as the power 
over suppliers increases. The potential synergies are valued at $28,522.8 million, of which 
$16,739.2 million are more likely to be realized. The combined firm, after the introduction of 
synergies, is expected to generate the same or even higher returns than the sum of the stand-
alone businesses and higher growth rates, fulfilling Amgen’s need of growth. 
 
Abstrato 
O objetivo desta dissertação é estudar a hipótese de uma aquisição na indústria biotecnológica, 
entre a Amgen (comprador) e a Incyte (empresa-alvo). A Amgen é uma empresa biotecnológica 
sedeada nos Estados Unidos da América que se depara com um decréscimo na venda dos seus 
produtos, principalmente devido ao aumento da venda de medicamentos genéricos e do 
crescimento de produtos biossimilares. De forma a compensar o seu fraco desempenho, a 
empresa procura uma aquisição na sua indústria, sendo a empresa Incyte uma possível escolha. 
A Incyte pertence à indústria biotecnológica americana, e, apesar de ter uma presença tímida 
no mercado com apenas dois produtos comercializados, espera-se que num futuro breve, as suas 
receitas aumentem significativamente. A combinação destas duas empresas permitiria uma 
transferência de conhecimento relativamente à pesquisa e processo de desenvolvimento de 
novos medicamentos, uma presença mais forte na Europa e ainda um maior poder de 
investimento para aplicar em Inovação & Desenvolvimento. A nova empresa teria a 
possibilidade de diminuir o número de trabalhadores devido à duplicação de postos de trabalho 
e diminuir os custos das vendas, por exercer um maior poder sobre os fornecedores. As sinergias 
foram avaliadas em $28,522.8 milhões, sendo que $16,739.2 milhões são as mais prováveis de 
serem realizadas. É expectável que a empresa combinada, após a introdução das sinergias, gere 
os mesmos ou maiores retornos, se comparada com a soma dos retornos das duas empresas 
separadamente, e maiores taxas de crescimento, preenchendo, assim, as necessidades de 
crescimento da Amgen. 
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On February 2018, the American biotechnology giant Amgen announced a new strategy: 
acquire a company of the same industry, to overcome the weak results of 2017 and to apply its 
excess cash in a more profitable way. 
This thesis presents the hypothesis of Amgen acquiring Incyte, another biotechnology 
company, and analyses both companies involved and the synergies that could arise from the 
combination of the two firms. 
In the second chapter, the existing literature on Mergers and Acquisitions (M&A) is reviewed, 
where important topics such as drivers of M&A, valuation techniques, and synergies are 
discussed. 
Then, the industry, its characteristics and the prospects for the future are analysed. The 
companies are also analyzed in chapter 4, where important information about the history of the 
companies and historical performance is discussed. 
In chapter 6, the companies are valued under different methods, and in chapter 7, it is discussed 
the potential synergies arising from the acquisition and their valuation. 
In chapter 8, details about the transaction are debated, such as the price to pay and the method 
of payment and in chapter 9, the post-merger integration is planned and discussed. 




2. Literature Review 
2.1. Mergers and Acquisitions 
2.1.1. Drivers of M&A 
To merge with or to acquire another company is one of the drivers of revenue growth in a 
business and it represents the inorganic growth a company can achieve by buying and selling 
revenue growth. M&A affect the economic activity as they can influence industry 
concentration, competitiveness, productivity growth, or technology transfer. They often come 
in waves, following the economic cycle and as a response to it. Therefore, their success is very 
dependent on the context of the deal.   
Several factors are suggested as inducers of the M&A activity such as synergies, diversification, 
use of excess cash, or market power, but not all of them have be proven to create value for both 
companies involved. 
Synergies are the main reason companies do M&A. They can be operational (revenue 
enhancements and cost savings) or financial, and they are perceived differently by investors, as 
cost savings are usually more achievable.  As several studies report, the expected synergies are 
a very important driver of M&A, and the deal will be successful if synergies are credible and 
realistic (Bruner, Where M&A Pays and Where It Strays: A Survey of the Research, 2004). 
Focusing on acquiring companies in a related field gives more room to exploit synergies, such 
as cost savings or asset reductions. Research on this factor has shown that focus on related 
businesses works better than diversifying (Bruner, Where M&A Pays and Where It Strays: A 
Survey of the Research, 2004). 
Most of the research shows that using excess cash to perform acquisitions is associated with 
value destruction. On the other hand, other study reveals that pairing “slack-poor” and “slack-
rich” companies tend to increase value. This suggests that using excess cash can destroy value 
unless when it is used in a profitable way (Bruner, Where M&A Pays and Where It Strays: A 
Survey of the Research, 2004). 
Increasing market share by performing horizontal mergers or acquisitions has been proven to 
provide positive returns. However, a larger market share does not improve wealth due to 
stronger market power, but rather by the synergies created by the combination of two companies 
that are very similar and use the same resources (Bruner, Where M&A Pays and Where It 
Strays: A Survey of the Research, 2004). 
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Research provides empirical evidence on which rationale is more profitable for the companies 
when doing M&A. When choosing a target, companies should be aware that different 
motivations have different reactions in the market and they can influence the success of the 
deal. 
 
2.1.2. Is M&A worth it? 
Several factors can drive M&A between firms. But, as years of deals have already shown, not 
all of them have been proven to be worth the money. In this section, a summary of studies that 
analyse whether a deal is worth it or not is presented.  
Target’s shareholders earn returns that proved to be both significantly and materially positive, 
which means the effect is large enough for shareholders or society to notice. For buyer’s 
shareholders, returns are harder to understand. Some studies found their returns to be significant 
and materially negative, but others present results where most of the deals seemed to either 
preserve or create value. But considering all studies in aggregation, it can be concluded that 
buyers break even, meaning they tend to receive the required rate of return (Bruner, Where 
M&A Pays and Where It Strays: A Survey of the Research, 2004). 
Other studies look at the financial performance of acquirers before and after the merger to 
understand the transaction’s impact on the performance. A study based on the largest 50 
mergers in the US between 1979 and 1984 concluded that the asset productivity of the buying 
firms improved after the deals, which was reflected on the higher operating cash flow returns 
when compared with their non-acquirer peers (Healy, Palepu, & Ruback, 1992).  
To summarize, target’s shareholders would agree that M&A pays off, since they tend to have 
positive returns, however, buyer’s shareholders do not receive, most of the time, more than the 
required rate of return. In addition, companies involved in M&A seem to improve their 
performance after the deals.  
 
2.1.3. Synergies 
Synergies are defined as the additional value generated by the combination of two firms, which 
would not exist if the two firms were operating independently. As referred in the first section, 
it is the most used rationale for M&A.  
4 
They can arise in two forms, operational or financial synergies. Operational synergies affect the 
operations of the combined firm and are related with economies of scale, increases in pricing 
power, combining functional strengths and higher growth potential. Financial synergies arise 
from tax benefits, higher debt capacity and lower interest expense, and more opportunities to 
use excess cash (Damodaran, The Value of Synergy, 2005).  
When an acquirer intends to buy another company, it usually offers more than the market value 
of the target. This difference, also called the premium, represents the value of synergies 
expected to arise from the combination of the two firms (Eccles, Lanes, & Wilson, 1999). 
However, synergies are forecasted, and the buyer can only be certain they will be realized once 
both firms are effectively combined. Nevertheless, the premium must be paid upfront. 
In addition, not all types of synergies have the same likelihood of being realized. Research 
suggests that synergies related with the elimination of duplicated functions and activities are 
the easiest to achieve, followed by the reduction in operating costs and facilities rationalization. 
The harder synergies to achieve are related to revenues enhancements (Cullinan, Le Roux, & 
Weddigen, 2004).  
Synergies are a very sensitive topic in M&A, as they are the main driver of deals. It is very 
important that acquirers value them correctly to avoid overpayments and take advantage of 
them once they are realized. 
 
2.1.4. M&A Approach 
Primarily, it is important to discuss whether the deal is a merger or an acquisition. A merger 
implies that two firms are combined, and a new firm is created. An acquisition involves a buyer, 
who purchases a stake higher than 50% in another firm, which is the target. A research 
performed an analysis of several studies on acquisitions and concluded that in successful 
mergers, bidders’ returns are zero, but in successful takeovers, bidders have positive returns 
(Jensen & Ruback, 1983).  
Then, it is necessary to decide how to approach the target. Research finds evidence that avoiding 
the target’s management and directly make an offer to shareholders creates more value than 
friendly approach the firm. Because this strategy involves convincing target’s shareholders to 
sell their share, the premium paid is usually high, benefiting those investors (Bruner, Where 
M&A Pays and Where It Strays: A Survey of the Research, 2004). 
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Finally, the method of payment should be analysed. Deals paid in stock seem to provide buyer’s 
shareholders negative returns, whereas cash-based deals have a neutral or slightly positive 
impact on returns but provide target’s shareholders considerably higher returns (Bruner, Where 
M&A Pays and Where It Strays: A Survey of the Research, 2004). 
 
2.2.M&A in the Healthcare Industry 
Research suggests that there are three main drivers of M&A in the pharmaceutical industry 
which are the escalating R&D investment costs, patent expirations, and increasing marketing 
costs. To strengthen the market position and respond to the intense competitive pressure in the 
industry, companies merge or acquire through two main strategies. They either acquire small 
pharmaceutical or biotech companies to strengthen the in-house Research & Development 
(R&D) or they merge with direct competitors and take advantage of economies of scale and 
scope in their R&D programs (Demirbag, Ng, & Tatoglu, 2007). 
The same study compares pharmaceutical companies involved in M&A and its peers that were 
not involved in M&A. It founds that M&A does not decrease performance when using Return 
on Invested Capital (ROIC) as a performance measure, but when using Profit Margin, 
companies involved in M&A performed better than non-M&A companies in the post-M&A 
period. This suggests that engaging in M&A allowed companies to take advantage of economies 
of scale and scope, and also indicates a better management of supply and distribution channels. 
Comparing the benefits of mergers and acquisitions in this industry, research finds that mergers 
provide no abnormal returns to shareholders and there is no improvement of Return on Equity 
(ROE). On the other hand, takeovers provide positive abnormal returns, in short, and long-term. 
Although acquisitions seem to perform better, they only account for 36% of all the transactions 
(Hassan, Patro, & Wang, 2007). 
 
2.3.Valuation Techniques 
Behind every decision of M&A, companies, and experts in the field use several techniques that 
allow the estimation of the true fair value of the unit to be acquired or merged. In the past 25 
years, a trend towards more formal and institutionalized models has become more explicit 
(Luehrman, What's It Worth? A General Manager's Guide to Valuation, 1997).  
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In the following sections, the models that proved to be more accurate in the recent past (Kaplan 
& Ruback, 1996) are presented, as well as their advantages and limitations. 
 
2.3.1. Cash-Flow Based Valuation 
The Discounted Cash Flow (DCF) model discounts to the present the future Free Cash-Flows 
(FCF), which is the cash-flow available to both equity and debt holders, and any other nonequity 
investor, at the appropriate discount rate, that should reflect the risk of the expected cash-flows. 
The enterprise DCF model gives the Enterprise Value, which is then subtracted from the market 
value of debt and other nonequity claims, to obtain the Equity Value.  
 
Weighted Average Cost of Capital 
The most commonly-used DCF model discounts the future cash-flows using the Weighted 
Average Cost of Capital (WACC), which assumes the capital structure remains constant 
throughout the period. This is the simplest version of the model since cash-flows are discounted 
always at the same rate. 
The WACC represents the returns that all investors in a company expect to earn from their 
investments in a business instead of investing the same funds in others with similar risk. 
Therefore, the WACC takes into consideration the cost of equity and the after-tax cost of debt, 
weighted by the company’s capital structure. 
Although it is easily applied, using a constant WACC in a DCF model has drawbacks that can 
make its use less convincing. It assumes that the company to be valued does not expect its 
capital structure to change. To be correctly applied, one should compute for each year a specific 
WACC, which is both difficult and time-consuming (Kaplan & Ruback, 1996). In its basic 
structure, it only addresses tax effects, and when a company has a complex capital structure, it 
struggles to give accurate results (Luehrman, Using APV: A Better Tool for Valuing 





2.3.2. Comparable Valuation 
A Comparable Valuation, also known as Multiples, has also proven to be accurate in valuing 
companies (Kaplan & Ruback, 1996). The idea behind this type of valuation is that similar 
assets should be sold at similar prices. Therefore, similar companies should be traded at similar 
prices, as well.  
The price of an asset can be obtained through two different multiples: industry or transactions 
multiples. Industry multiples allow the comparison between companies or assets in the same 
industry, with similar performance. Transaction multiples are based on recent and similar 
transactions of the same type asset. 
A Comparable Valuation is simple and easy to perform. Also, some multiples incorporate data 
from the capital markets, which reflect the expectations from investors. However, some 
multiples are easy to manipulate, because some items can be changed to get good multiples 
(depreciation or provisions). Besides, a good peer group is necessary to be able to compare 
companies accurately. 
Both DCF model and Comparable Valuation already proved their utility to perform company 
valuation. As they provide different insights of valuation, the two techniques should be 
combined, to get more robust and accurate results (Kaplan & Ruback, 1996). 
 
2.4. Post-Merger Integration 
The Post-Merger Integration (PMI) is one of the main topics of discussion nowadays when it 
comes to M&A deals. It refers to the process that happens after a deal is finished and where the 
two businesses are merged, and the assets of the combined firm suffer changes to achieve the 
expected synergies (Bodner & Capron, 2018). 
Research shows that managers are starting to pay attention to this issue, as it seems to have a 
huge impact on the success of the deal (EY, 2014). It shows that, for managers, it is important 
to focus on the core of the acquisition, allocate resources to the integration and make sure that 
all the measures needed to achieve synergies are effectively implemented, and if necessary, 
proceed to a second wave of integration. Although companies are starting to invest more in this 
phase, the research shows that managers, in retrospective, would have invested more in 
integration.   
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3. Industry Analysis 
The Industry 
The healthcare industry is one of the most important industries in the world. Not only because 
of its main purpose of positively impacting the global health, by saving lives, increasing 
lifespan, or reducing pain, but also because of its impact on the economy. The United States 
(U.S.) has the largest healthcare market in the world, accounting for $444 billion in sales in 
2016, more than twice the sales in Europe or Emerging Markets (Figure 1 - Global 
Pharmaceutical Sales in 2015 and 2016, by region  (Statista, 2017)). The U.S. market has grown 
an average of 6% in the past years, only behind China and Brazil (Statista, 2017).  
 
Figure 1 - Global Pharmaceutical Sales in 2015 and 2016, by region (Statista, 2017) 
 
The healthcare industry is divided into 4 different segments and includes companies that 
manufacture drugs (Pharmaceuticals), produce medical equipment (Healthcare Equipment & 
Supplies), provide medical services (Healthcare Providers & Services), or focus mainly on 
research and development of new products (Biotechnology and Medical Research) (Thomson 
Reuters Eikon, 2018).  
Although belonging to the same industry, the two companies involved in the acquisition 




































pharmaceuticals segment and Incyte, the target, belongs to the biotechnology and medical 
research segment.  
The main difference between pharmaceutical and biotechnology companies relies on the 
components used to develop drugs. Pharmaceuticals base their drugs on chemicals and artificial 
materials, whereas biotechnology companies use live organisms to produce their medicines. 
Furthermore, pharmaceuticals usually manufacture their own products, while the biotechnology 
companies contract with 3rd parties for the manufacturing, focusing mainly on the research of 
new treatments (Investopedia, 2018). 
Despite belonging to the pharmaceuticals segment, Amgen is a biotechnology company, since 




As a result, the analysis of the industry relies solely on the biotechnological sector, as Amgen 
is exposed to similar risks as Incyte. The analysis is based on Porter’s 5 Competitive Forces, 
which allows the study of the main risks a company faces within an industry: entry barriers, 
rivalry within the industry, pressure from substitutes, and power of customers and suppliers 
(Porter, 1998). 
In the biotechnology segment, the barriers imposed to new entrants are high mainly due to the 
high level of investment in R&D  needed to develop new pharmaceuticals and the government 
policy  this sector is subject to, as it takes years of analysis and tests until new drugs become 
marketable (Amgen Inc., 2017) (Incyte Corporation, 2017). However, in the U.S. there is a 
supportive environment on this topic, as the intellectual property system rewards innovation 
through patent and data protection, encouraging R&D investments (International Trade 
Administration, 2016). 
Biotechnological companies face intense rivalry within the segment and within the industry 
(International Trade Administration, 2016) (Amgen Inc., 2017). All companies want to 
guarantee that their investments in R&D are worth it, by assuring they have as many products 
in the market as possible. Also, several companies produce products that treat the same 
conditions, increasing the competition between them. 
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Companies in the industry face a moderate pressure from substitutes as products that are not 
protected by patents face the risk of being replaced by similar drugs, inducing an intense 
competition (Investopedia, 2017). However, for products protected by patents, there is no 
competition, as other companies cannot replicate them. 
Suppliers do not have a lot of power over these firms, as there are several companies that can 
supply the generality of the materials (Incyte Corporation, 2017). However, there are some 
medical devices and raw materials that are supplied by specific 3rd parties, making the 
companies highly dependent on them (Amgen Inc., 2017).  
Finally, although government health systems and private healthcare institutions tend to pressure 
firms in terms of pricing, the U.S. has the world’s largest free-pricing market for drugs, making 
this pressure from buyers relatively low (International Trade Administration, 2016). 
 
Outlook 
For the next years, two trends are being traced regarding the future of the healthcare industry. 
First, the rising of biosimilar products, which are biological versions of products already 
approved, which now account for over a third of the products in clinical trials or awaiting 
approval from the Food and Drug Administration (FDA). Second, the growing use of generics, 
as its consumption already represents a quarter of total drugs sold, mainly due to the expiration 
of several patents and the reforms in the industry that favour the use of these products, since 
they are more affordable for patients (International Trade Administration, 2016). Although 
some companies may struggle to fight these products, the sector is expected to experience 
continuing growth, not only through the level of new drugs launched but also by an increasing 
level of M&A activity in the industry, as an alternative for R&D investments (Euler Hermes 




4. Companies Analysis 
4.1. Amgen Inc. 
Amgen’s mission is to serve patients through exploring the potential of biology to treat serious 
illnesses, by delivering innovative human therapeutics. It focuses on areas of highly unmet 
medical needs and makes major investments in expertise to find solutions that improve health 
but also improve people’s quality of life. It has experienced an increasing growth, becoming 
one of the world’s leading biotechnology companies. 
Amgen was created in 1980 in Thousand Oaks, California by a group of venture capitalists. 
Three years later, the company decides to become public, raising around $40 million. In the 
following years, two of the most important drugs developed by Amgen are approved by the 
FDA. EPOGEN® and NEUPOGEN®, to treat anemia and infections, respectively, are named 
Product of the Year by Fortune magazine once they are launched. 
In 1994, Amgen becomes the first biotechnology company to receive the National Medal of 
Technology, and in the following years, Enbrel® for rheumatoid arthritis, Aranesp® for anemia, 
Neulasta® for cancer patients, Sensipar® for kidney diseases, XGEVA® for bone conditions, 
Vectibix® for colorectal cancer, Nplate® for blood problems, and Prolia® for osteoporosis are 
approved by the FDA. Currently, it is preparing the launch of a new product, 
AMJEVITA®/AMGEVITA®, for inflammatory diseases, in both Europe and the U.S., which 
will be released in five years. 
From the 2000s onwards, Amgen settled several partnerships with other companies in the 
industry to develop and commercialize specific products. One example is the collaboration with 
Actavis to develop and commercialize several oncology antibodies. The more recent 
partnership is with Bayer HealthCare Pharmaceuticals Inc., to jointly develop and 
commercialize Nexavar® for oncology patients. 
Amgen has also acquired several other companies such as Immunex (2002), deCODE Genetics 
(2012), and Onyx – Pharmaceuticals (2013).  
Amgen has strong marketing channels in the U.S. and has a strong monitoring system which 
controls its customers and suppliers to limit its credit exposure. On the other hand, Amgen 
highly depends on three large wholesalers in the U.S. and on specific 3rd parties who supply 
certain raw materials and medical devices. Furthermore, the company is facing increasing 
competition from biosimilar products and generic drugs and its sales are highly dependent on 
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government healthcare systems and private health insurance, that want to reduce its costs with 
pharmaceuticals. 
It has 16 marketed products and has 35 patents registered in the U.S. and in Europe that not 
only protect chemical substances but also formulations and methods of treatment, which 7 of 
those expiring until 2020. 
At the same time, Amgen is researching and developing new drugs and treatments, which builds 
a solid and extended pipeline of products. It has 17 products in Phase I, mainly treating bone 
diseases and asthma, 5 in Phase II for atopic dermatitis and lymphoma conditions and 11 in 
Phase III, in development to treat leukemia, inflammation, and heart failure. It is also 
developing biosimilar products, which have a different process of testing. 
Currently, Amgen has a market capitalization of $123 billion (as of 01.02.2018), being the 5th 
largest company in the pharmaceutical segment and the 6th in the overall healthcare industry.  
 
Figure 2 - Amgen's Stock Price Evolution and S&P 500 (Wharton University of Pennsylvania, 2018) 
 
After becoming public, Amgen’s stock price traced a trend of growth, with several picks along 
the way. The first big increase in the stock price occurred between 1989 and 1991, right after 
the launch of the first drugs developed by Amgen. The second pick, around 1998, was caused 
by the launch of the 3rd product launched, Enbrel®. After surviving the financial crisis with low 
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of the S&P 500. As of 01.02.2018, Amgen’s stock price was at $185.56 and trying to recover 
from a decrease caused by the release of the results of 2017 (Figure 2 - Amgen's Stock Price 
Evolution).  
In 2017, it was the 7th company in the industry with the largest revenues (Figure 3 - Revenues 
of Top10 biotech and pharmaceutical companies in 2017). 
 
Figure 3 - Revenues of Top10 biotech and pharmaceutical companies in 2017 (Statista, 2017) 
 
In the last 10 years, revenues grew at an average rate of 4.4%, despite the decrease in sales in 
the past year. This decrease was mainly due to lower unit demand for several products and 
smaller royalties and revenues derived from corporate partnerships. The most important drug 
in terms of sales is Enbrel®, which accounted for around 24% of total sales in 2017 (Exhibit 
11.1 Amgen’s Historical Revenues). 
In the last fiscal year, Amgen spent approximately 16% of 2016’s Revenues in R&D 
expenditures, below the average of 20% of the historical period. Nevertheless, this value is in 
accordance with the pharmaceutical industry, which spent on average 19.8% of total revenues 
in 2015 (Statista, 2017). 
Amgen has increased its operating margins to levels above the industry. It has an average 
EBITDA margin (EBITDA/Revenues) of 42% in the last 12 years, where the highest value was 
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registers values around 32% (Damodaran, Margins by Sector (US), 2018). From the NOPLAT 
it was derived the Net Income, which had a tendency to grow until 2017 when it registered the 
lowest value of the period due to a Non-Recurring Tax Change Expense (Exhibit 11.3 Amgen’s 
Historical Net Income). If this expense was excluded, Amgen’s Net Income would have been 
$8,079 million. 
Regarding the capital structure of the company, the percentage of debt has increased from 2008 
until 2012, when it almost represented 60% of total capital, but has decreased since then to 
49.3%. The average debt-to-capital ratio of the historical period was 46%, which is below the 
average ratio for the biotechnology industry (48.4%), but higher when compared with the 
average of the pharmaceutical industry (40.7%) (Damodaran, Debt Fundamentals by Sector 
(US), 2018) (Exhibit 11.4 Amgen’s Historical Invested Capital and Exhibit 11.5. - Amgen’s 
Historical Equity and Debt).  
The FCF Statement has been quite irregular, registering values between -$12,254.0 million and 
$10,411.3 million, since both components, Gross Cash-Flow and Gross Investment tend to vary 
significantly throughout the historical period (Exhibit 11.6. Amgen’s Historical Free Cash-
Flow Statement). 
Amgen has managed to increase its Return on Invested Capital (without Goodwill) (ROIC) until 
2012, where it was able to deliver a return of 45.8%. However, since then, this value has been 
decreasing and has been quite unstable, but on average, the return was 34%. This instability is 
also verified in the Return on New Invested Capital (RONIC) (without Goodwill), which has 
been very volatile, reaching both negative and positive, high and low values. In 2017, Amgen 
provided a return on newly invested capital of 146.6% (Exhibit 11.7. Amgen’s Historical 
Financial Ratios). 
 
4.2. Incyte Corporation 
Incyte’s objective is to become one of the leading biotechnology companies in the world and 
believes that investment in good science and rigorous research and development of new drugs 
ultimately translates into medicines that can affect positively people’s lives. 
Incyte was found in Palo Alto, California on April 1991 but currently is based in Wilmington, 
Delaware and its focus is the discovery, development, and commercialization of therapeutics. 
Two years after the foundation, Incyte decides to go public, raising around $17 million.  
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From the beginning of its activity until 2003, Incyte was focused mainly on gene analysis, 
creating the world’s most extensive and comprehensive “genetic encyclopedia”. After a decline 
in this sector of biotechnology, Incyte decided to change its core business and started to focus 
only on drug discovery, mainly treating oncological problems.  
The first marketed product was JAKAFI®, approved by the FDA in 2011 and developed to treat 
patients who suffer from myelofibrosis and patients with polycythemia vera, which is the first 
product, and still is, to treat two types of blood cancer. Incyte also developed IncyteCARES, 
which ensures that all patients in need for JAKAFI® get the medicine.  
Incyte has other products on the market that were developed in business partnerships with other 
companies in the sector. One example is the collaboration with Novartis International 
Pharmaceutical, Ltd., which started in 2009, and gave both companies the right to develop and 
commercialize the JAK inhibitor ruxolitinib in and outside the U.S. In 2016, it acquired ARIAD 
Pharmaceuticals, Inc., allowing Incyte the commercialization of Iclusig®, used to treat 
leukemia, in the European Union and 22 other countries. 
Incyte is highly dependent on the success of JAKAFI® and Iclusig® and is also very dependent 
on 3rd parties to manufacture all of its products. It has limited resources to perform the expensive 
clinical trials, but without those, it cannot get approval from the FDA. 
In addition, Incyte has 7 patents in the U.S. and 8 in Europe, all of them valid for a minimum 
period of 8 years. 
Regarding the pipeline of products in development, Incyte has 9 products in Phase I focused in 
treating solid tumors and some types of cancer, 16 in Phase II to treat lymphomas and advanced 
malignancies, and 15 in Phase III, developed for patients with cancer, psoriatic or atopic 
dermatitis. 
Incyte has a market capitalization of almost $19 billion (as of 01.02.2018) and its stock price 
evolution has had a turbulent path. Until 2003, the year Incyte changed its core business, the 
stock price had a pick and reached values close to $140, in the dot.com bubble crisis. After 
changing the core business, Incyte’s stock price has had a modest tendency to grow and since 
2010, the stock price has been rising more expressively, although having some declines 
throughout the period. However, in the last year it has been registering a tendency contrary to 
the benchmark (Figure 4 - Incyte's Stock Price Evolution). 
16 
 
Figure 4 - Incyte's Stock Price Evolution and S&P 500 (Wharton University of Pennsylvania, 2018) 
 
In 2017, it registered revenues of $1,536 million, representing an increase of 39% relative to 
2016, but a negative net income of $313.1 million, contrary to the last 2 years. The revenues 
have had an average growth of 197% in the historical period and until 2011, the company only 
had revenues from royalties paid by corporate partners. In 2011, Incyte released the first drug 
and started to have revenues derived from the sale of its products (Exhibit 11.8. Incyte’s 
Historical Revenues). 
Incyte has not been able to provide positive results because it is still making high investments 
in R&D that are much bigger than those of the industry. Incyte spent, on average, 535% of 
Revenues in R&D in the historical period. Regarding the EBITDA margin, Incyte had for 
several years negative EBITDA, making this ratio negative for most of that period. In the last 
5 years with positive EBITDA, the average EBITDA margin was 7.8%, positioning Incyte far 
away from the average of the biotechnology industry (31.3%) (Damodaran, Margins by Sector 
(US), 2018) (Exhibit 11.9. Incyte’s Historical NOPLAT). Incyte has had negative Net Income 
for almost all the historical period, with only 2015 and 2016 standing out with positive results 
(Exhibit 11.10. Incyte’s Historical Net Income). 
In the historical period, Incyte has increased the level of debt, except for 2017, where the value 
decreased drastically. Nonetheless, on average, debt represented 129% of total capital. This 
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(Damodaran, Debt Fundamentals by Sector (US), 2018) (Exhibit 11.11. Incyte’s Historical 
Invested Capital and Exhibit 11.12. Incyte’s Historical Equity and Debt). 
Incyte was able to generate only one positive cash flow during the historical period. Until 2015 
the Free Cash-Flow seemed to create a tendency to become positive, however, the values of 
2016 and 2017 were revealed to be the most negative ones of the period (Exhibit 11.13. Incyte’s 
Historical Free Cash-Flow Statement). 
Nonetheless, Incyte has been able to provide positive results on invested capital. On average, 
the ROIC without Goodwill was 97.5%, and although it was very volatile, it did not register 
high negative values. On the other hand, the RONIC was very unstable and registered an 




5. Deal Rationale 
On February 11th, 2018, Amgen’s Chief Financial Officer, David Meline, informed that Amgen 
was looking for a target company to buy and invest in (Crow, 2018). Mr. Meline claimed that 
Amgen had the financial flexibility to acquire a new business, and the only reason a deal was 
not announced yet, was the huge premiums companies in pharmaceuticals are paying for 
acquisitions. The main objective is to invest in a life sciences/healthcare company and still 
provide a good return to shareholders. Considering the decrease in sales in the last fiscal year 
and the expiration date of some important patents coming closer, Amgen has decided to take a 
new growth strategy through M&A.  
As suggested by the literature in the pharmaceutical industry, companies follow one of two 
strategies: acquire a smaller pharmaceutical or biotechnology companies or merge with large 
competitors to increase market share. For this thesis, it was assumed that Amgen would pursue 
the first strategy because acquisitions seemed to provide higher positive returns when compared 
with mergers. 
As a result, and after an analysis of potential targets, Incyte came out to be a good option for 
this acquisition. Incyte is a company that only had positive earnings in 2015 and 2016 and is 
still making high investments in R&D to increase future revenues. However, it has a great 
potential and a very positive outlook for future revenues (Thomson Reuters Eikon, 2018), which 
can offset the low results Amgen is facing. 
On the other hand, Amgen has already several marketed products and strong marketing 
channels that can also improve Incyte’s performance in delivering new drugs. It has a strong 
presence in Europe, which can help Incyte in its new European operations. Also, Amgen has a 
strong drug development process, which is a weakness for Incyte. In addition, both companies 
have similar drugs in development, allowing knowledge transfer and improvement of 
treatments’ results, as well as increase the number of future patents and guarantee future profits. 
For example, both companies are developing drugs to treat atopic dermatitis, and they are both 
in Phase II of development. Therefore, the new combined company can use knowledge and 
resources from the two companies to achieve a better result more efficiently. Another example 
is the fact that Amgen has a product in the market to treat rheumatoid arthritis and Incyte is 
developing a new drug to treat the same condition. As a new product would not affect negatively 
the overall revenues, Amgen can help Incyte with expertise in the development of the new drug.  
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6. Valuation 
To provide a clear valuation of both companies, it is necessary to forecast how the company 
will behave in the future. Therefore, assumptions are needed for the different items of the Net 
Operating Profit Less Adjusted Taxes (NOPLAT) and the Total Funds Invested Statements, as 
well for all the components of the FCF Statement. 
 
6.1. Amgen Inc. 
6.1.1. Financial Projections 
For each item of the NOPLAT Statement, it is necessary to forecast the value for the next 10 
years. As it can be less accurate to predict the firm’s behaviour 20 or 30 years from now with 
detail, the remaining years will be calculated as a perpetuity, considering the historical 
performance of the company. 
Revenues are the main driver for most of the components of the statements, meaning their 
prediction is extremely important. The acquirer’s projected revenues from 2018 until 2022 were 
based on the estimates from analysts (Thomson Reuters Eikon, 2018), which are specialists in 
the industry and follow the company for some years (Exhibit 11.15. Amgen’s NOPLAT 
Forecast). These estimates assume an average growth rate of 1.2% throughout the 5 years. This 
average growth rate was then applied to the remaining years of the forecast period, which 
assumes the company will continue the same behaviour as before. 
Regarding the Operating Expenses, they were all forecasted based on the value of Revenues 
(Exhibit 11.16. Amgen’s NOPLAT Forecast Drivers). For the item Cost of Sales (also referred 
as Cost of Goods Sold (COGS)), it was used the percentage of Revenues of 2016 (18.1%), once 
the value of 2017 included some non-recurring expenses. Regarding the R&D Expenses, it was 
forecasted to be the average of the last 3 years (17.8%), as it is in line with the expenses of the 
industry. For the future costs with Selling, General and Administrative (SG&A), it was assumed 
the percentage of Revenues of 2017 (21.3%), since in this year the payment of royalties of the 
sale of Enbrel® ended, making the value of 2017 a good indicator to the future behaviour of this 
item. For Other Operating Expenses item, it was assumed that the future percentage of 
Revenues would be the average percentage of Revenues of the last 6 years, as this item is very 
volatile and using only a few years could bias the estimation. The use of 6 years is related to 
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the fact that in 2011 there was a legal settlement, which is a non-recurring expense, and should 
not be considered as an indicator for future performance. 
Depreciation and Amortization forecasts were based on previous year’s Net Property, 
Equipment and Plant (NPPE) and Net Intangible Assets, respectively. However, both 
Depreciation and Amortization were split into two different segments: one for assets registered 
in 2017 and the other for new assets derived from new investments. In 2017, Net PPE had a 
value of $4,989 million, and that value was depreciated over 10 years. For Depreciation of new 
investments, it was assumed that it would be the average depreciation in NPPE of the last 3 
years, which was 13.2%. For Amortization of “older” Intangibles, it was followed the 
Amortization schedule planned in Amgen’s 10-K until 2022, which amortizes $5,200 million 
from the value registered in 2017. After 2023, it was amortized the value still left to amortize 
from 2017, which was $3,409 million. For Amortization of new investments, it was assumed a 
forecast ratio of 12.8% of Net Intangible Assets, as this was the relation between the variables 
in the past. 
Operating Taxes were assumed to be 32.6% of EBITDA, which was based on previous years’ 
Operating Taxes. 
Interest Expense and Interest Income were assumed to be 3.8% of previous year’s Total Debt 
and 2.3% of previous year’s Excess Cash and Marketable Securities, respectively, which were 
based on previous relations of these variables (Exhibit 11.17. Amgen’s Net Income Forecast). 
Regarding the components of Operating Working Capital, Inventories and Payables were 
forecasted using the average percentage of COGS of the last 3 years, which were 64.4% and 
26%, respectively. Operating Cash was assumed to be 2% of Revenues1, Receivables (13.9%) 
and Other Operating Current Liabilities (24%) forecasts were based on the average percentage 
of Revenues of the last 3 years, and Other Operating Current Assets were assumed to be 9.9% 
of Revenues, which is the average percentage of the last 7 years, since this is a very volatile 
item (Exhibit 11.18. Amgen’s Invested Capital Forecast).  
Investments in NPPE and in Net Intangible Assets were also assumed to be related with 
Revenues. As these investments vary significantly, the average percentage of Revenues of the 
last 7 years was assumed for the forecast period. Therefore, investments in NPPE were assumed 
to be 3.1% of Revenues and investments in Net Intangible Assets 6.7% of Revenues. The values 
                                                          
1 Research found out that companies with small cash balances hold cash around 2% of Revenues, making this a 
reasonable proxy for Operating Cash (Koller, Goedhart, & Wessels, 1990) 
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of NPPE (Net Intangible Assets) were then the sum of the previous year’s value and the current 
year’s investment, less the Depreciation (Amortization). 
For reasons of simplicity, it was assumed that Goodwill would remain constant, which implies 
that the company is not going to be involved in M&A in the future. 
The forecasted components of Equity and Debt are presented in Exhibit 11.19 Amgen’s Equity 
and Debt Forecast. 
 
6.1.2. Discounted Cash-Flow Model 
One of the models used to value the company was the DCF model, which values the company 
by discounting the FCF of the explicit period at the WACC, which is the return required by all 
investors of the firm.  
This model was chosen over the Adjusted Present Value (APV) since the capital structure does 
not vary significantly throughout the period. Therefore, the WACC does not suffer significant 
changes, not requiring the use of the APV model. 
 
6.1.2.1. Free Cash-Flow Estimation 
To discount the FCF it was necessary to estimate its value for all the years in the explicit period. 
For the remaining years, the Continuing Value (CV) was computed. 
Exhibit 11.20. Free Cash-Flow Statement Forecast shows the FCF estimation, based on some 
of the items previously forecasted. The first component of the FCF is the Gross Cash Flow and 
includes NOPLAT, Depreciation, and Amortization, as they represent the cash-flow that stays 
in the firm. The second component is the Gross Investment and includes all the items that reflect 
investments made by the firm. After subtracting the Gross Investment to the Gross Cash Flow, 
the FCF is obtained. 
The CV was computed with the formula  






As it replicates the process of discounting the future cash-flows to the present. 
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𝑁𝑂𝑃𝐿𝐴𝑇𝑡+1was computed using the 2027’s NOPLAT and its last growth rate (1.3%), 𝑔 is the 
growth rate of the Free Cash-Flow in the last year (1.1%) and RONIC is the one of the last year 
of the explicit period (8.2%). This value reflects how much the company is worth considering 
the years after 2027. Applying the formula, it was given a value of $84,222.3 million for the 
CV. 
The FCF are discounted using the formula 






By summing all the discounted FCF and the CV, the Enterprise Value obtained is $120,020.8 
million. 
 
6.1.2.2. Weighted-Average Cost of Capital 
As explained before, the WACC is necessary to compute the present value of the FCF but also 
to compute the CV of the company. The WACC is computed using the formula 
𝑊𝐴𝐶𝐶 =  
𝐷𝑒𝑏𝑡
𝐶𝑎𝑝𝑖𝑡𝑎𝑙




The cost of debt (𝑘𝑑) was computed using the bonds issued by the company and the loans 
outstanding. For the bonds, it was computed the geometric average of the yields of the bonds 
with longer maturity (ending after 2040), which was determined to be 4.68%, which was 
averaged with the yield derived from the loans (4.27%), weighted by their respective values. 
The yield from the loans was based on Amgen’s rating (A-) (Thomson Reuters Eikon, 2018), 
from which was taken the spread over the 10-year Treasury Bond. The marginal tax rate (𝑇𝑚) 
was the one used for 2017, which was 35.3%. From this information, the cost of debt calculated 
was 4.47%. 
The cost of equity (𝑘𝑒) was calculated using the CAPM model 
𝐶𝐴𝑃𝑀 = 𝑟𝑓 + 𝛽 ∗ 𝑀𝑅𝑃 
Where 𝑟𝑓 is the yield of the 10-year Treasury Bonds (STRIPS), 𝛽 is the sensitivity of the 
company to the market and the 𝑀𝑅𝑃 is the Market Risk Premium. The value of the risk-free 
used was 2.98% (Thomson Reuters Eikon, 2018). The beta was based on Amgen’s peer group, 
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which was created using a cluster analysis. For this analysis, it was chosen a sample of 18 
companies, all from pharmaceuticals and biotechnology industries, as well as several indicators 
that characterized the companies (growth rate, capital structure, profitability, and multiples). 
The cluster analysis allows the creation of a peer group only based on this information, using 
only logical reasoning.  This way, it is ensured that the peer group is formed rationally, not 
including any personal judgement. It analyses all the information and creates groups of 
companies, called clusters, where companies are allocated based on their characteristics. 
Companies in the same cluster have similar characteristics. Testing for several numbers of 
clusters, Amgen ended up always with the same companies in its cluster: AbbVie and Gilead 
Sciences. The levered betas of the companies (1.54 and 1.08, respectively) were transformed 
into unlevered, taking into consideration each firm’s capital structure, and their average was 
assumed to be the unlevered beta of Amgen, which was 0.53. The levered beta of the acquirer 
was then calculated, using the formula 
𝛽𝑒 = 𝛽𝑢 +
𝐷
𝐸
(𝛽𝑢 − 𝛽𝑑) 
The final value was 1.7, considering a Debt-to-Equity ratio of 140.02% and a beta of debt (𝛽𝑑) 
of 0.32. For the Market Risk Premium, it was used the market returns3 and the risk-free returns4 
from 1941 to 2017. The final value of the market risk premium, 6.03%, was the value between 
the arithmetic (6.5%) and geometric average (5.6%), as none of the values is accurate enough. 
Having all the necessary information, the cost of equity was calculated, and the value was 
13.25%.  
For the remaining computation of WACC it was used the Debt-to-Capital (49.3%) and Equity-
to-Capital (50.7%) ratios, using Amgen’s data from 2017. It was used the Gross Value of Debt, 
since in the derivation of Equity Value, it will be added the Excess Cash and Marketable 
Securities to the Enterprise Value. If Net Debt was used, the addition of Excess Cash and 
Marketable Securities would not be needed, since it would imply a double-count of the same 
value (Damodaran, Investment Valuation, 2012). The value determined for WACC was 8.1%. 
 
                                                          
2 Assumption is based on the implied beta based on the spread between investment-grade corporate debt and 
government debt (Koller, Goedhart, & Wessels, 1990) 
3 For the market returns it was used the CRSP returns. 
4 For the risk-free returns it was used the returns on the 10 years US treasury bonds. 
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6.1.2.3. Equity Value 
By discounting the FCF and summing the CV, it is obtained the Enterprise Value. However, it 
is also necessary to derive the Equity Value. 
As referred previously, to obtain the Equity Value, the Excess Cash ($3,364.1 million) and the 
Excess Marketable Securities ($37,878.0 million) should be added to the Enterprise Value. 
Then, the Market Value of Debt (39,296.8 million), which was obtained through the value of 
the bonds outstanding and the current loans, should be subtracted. After these calculations, the 
Equity Value for Amgen determined was $121,966.1 million, which translates into a value of 
$184,3 per share. 
 
6.1.2.4. Sensitivity Analysis 
To understand how much the valuation would change if key assumptions were modified, it is 
necessary to perform a sensitivity analysis. The results are presented in the Exhibit 11.21. 
Amgen’s Sensitivity Analysis. 
If the cost of capital was estimated at a higher value, the discounted cash flows would be lower, 
as this would imply an increase in the risk of the company.  
If the growth rate in perpetuity was assumed to be almost half of the one assumed, the valuation 
would decrease, but it would not suffer a big impact. The same happens if the growth rate was 
assumed to be 1 pp. higher.  
If the Revenues growth rate for the last 5 years of the explicit period was the last growth rate 
of 2022 (3.4%), Revenues would grow at a much higher pace, inducing a higher NOPLAT, and, 
consequently, it would increase the valuation in almost $46,000 million. On the other hand, 
assuming the growth rate observed at the beginning of the explicit period, that would result in 
a decrease of the enterprise value to $95,580.7 million. 
Assuming that the forecasted R&D Expenses would be equal to the average percentage of 
Revenues of the last 7 years (20.4%), it would decrease the valuation in almost $9,000 million, 





The second valuation method used to compute the value of Amgen was the multiples approach, 
using the peer group from the cluster analysis and the multiples EV/EBITDA, EV/EBIT and 
EV/Revenues for each company. Based on these values and applying to the acquirer’s data, the 
results obtained are presented in the Exhibit 11.22. Amgen’s Multiples. 
The multiples EV/EBIT and EV/Revenues give the lowest values of the valuation, but very 
close to each other. The multiple EV/EBITDA increases the value of Amgen in more than 
$10,000 million, compared to the previous multiples.  
 
6.1.4. Valuation Summary 






Regarding the Enterprise Value, the multiples EV/EBIT and EV/Revenues give the closer value 
to the one given by the DCF Model, whereas the multiple EV/EBITDA gives the highest value, 






When it comes to Equity Value, EV/EBIT, EV/Revenues and DCF model give the closest 
values to the market value of the company. The Market Capitalization of Amgen as of 



















Figure 6 - Valuation range of Amgen's Equity Value 
Figure 5 - Valuation Range of Amgen's Enterprise Value 
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DCF model. DCF Model gives a value that differs only 0.7% of the Market Cap, whereas the 
multiple EV/EBITDA differs in 6.5%. 
 
6.2. Incyte Corporation 
6.2.1. Financial Projections 
The valuation of the target company, Incyte, was performed in the same framework as the 
acquirer. Therefore, the projections of Revenues were also based on analysts’ estimates and 
most of the NOPLAT and the Total Funds Invested Statements items depend on forecasted 
Revenues. The explicit period for Incyte’s forecasts is bigger once it is in a growing phase, and 
it was necessary to guarantee that the company reaches the steady state to obtain an accurate 
valuation. 
The first 5 years of Revenues of the explicit period were based on the estimates of analysts 
(Thomson Reuters Eikon, 2018). For the following 5 years, it was applied the average growth 
rate that was registered in the previous 5 years – 14.5%. For the final 5 years of the explicit 
period, it was applied the growth rate expected for the biotechnology industry (7.4%) (Grand 
View Research, 2017) (Exhibit 11.23. Incyte’s NOPLAT Forecast). 
The items Cost of Sales and Other Operating Expenses were forecasted based on the average 
percentage of Revenues of the previous 3 years, as this item has been quite stable in the last 
years. For R&D Expenditures it was applied two different percentages of Revenues. The 
percentage of Revenues of 2017 (93.8%) could not be used to forecast the following years, as 
this value includes an upfront and milestone expenses with clinical research, which is a non-
recurring payment. Therefore, the value of 2018 was computed with the values of 2017, 
excluding this payment. The values until 2022 were based on the percentage of Revenues of 
the value of 2018, which was 45.4%. And as the company has a higher percentage of Revenues 
than the one of the industry, it was assumed that after 5 years of the explicit period, the 
percentage would decrease to 40.4%, to get closer to the average of the industry. For SG&A, it 
was assumed the average percentage of Revenues of 2017 (42.7%), as it has been decreasing 
lately, and it was assumed it would continue to follow this trend (Exhibit 11.24. Incyte’s 
NOPLAT Forecast Drivers). 
From 2028 to 2032, only Revenues and NOPLAT were forecasted, since it is difficult to predict 
in such detail how the company will behave 10 to 15 years from now. Therefore, Revenues 
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were forecasted as explained above, and it was assumed that the NOPLAT would behave in the 
same way as before – it would represent 16.4% of Revenues. 
Similarly to Amgen, Depreciation, and Amortization was split into two different segments. The 
first was related to the NPPE and Net Intangibles as of 2017. For Depreciation, the value of 
2017 ($259.8 million) was depreciated over the 15 years of the explicit period, giving a 
Depreciation of 17.3. For Amortization, it was followed the schedule already planned in 
Incyte’s 10-K of 2017. Depreciation of new investments in PPE was assumed to be 15% of Net 
PPE and Amortization of new investments in Intangible Assets was forecasted to be 8.5% of 
Net Intangibles, all based in the last 3 years of the historical financials. 
Operating Taxes were assumed to be 1.7% of EBITDA, which is the average of the years with 
positive EBITDA. 
Interest Expense was assumed to be 4.7% of previous year’s Total Debt and Interest Income 
was forecasted to be 1.4% of previous year’s Excess Cash and Marketable Securities, all based 
in the relation between these variables in the last 3 years (Exhibit 11.25. Incyte’s Net Income 
Forecast). 
In Operating Working Capital, the items Inventories and Payables were assumed to be the 
percentage of COGS of 2017, which were 11.2% and 116.7%, respectively. Operating Cash 
was assumed to be 2% of Revenues, and Other Operating Current Assets was forecasted with 
the percentage of Revenues of 2017, 4.1%, as the values were stable during the historical period. 
For Receivables and Other Operating Current Liabilities, it was used the average percentage of 
Revenues of the last 3 years (17.4%), as the items were volatile (Exhibit 11.26. Incyte’s 
Invested Capital Forecast). 
Investment in NPPE and investment in Net Intangibles were assumed to be the average 
percentage of Revenues of the last 3 years, which is 7.6% and 8.3%, respectively. For 
simplicity, Goodwill was assumed to remain constant. 
The forecasted components of Equity and Debt are presented in Exhibit 11.27 Incyte’s Equity 





6.2.2. Discounted Cash-Flow Model 
6.2.2.1.Free Cash-Flow Estimation 
As explained before, the FCF is the difference between Gross Cash-Flow and Gross Investment, 
and for Incyte the results of the FCF statement are presented in Exhibit 11.28. Incyte’s Free 
Cash-Flow Statement Forecast. 
For the CV was used an average growth rate in perpetuity of 6.2%, which corresponds to the 
last growth rate of the Free Cash-Flow and a RONIC of 8%, based on the value of RONIC in 
the last year of the explicit period. Applying the formula referred earlier, the calculations give 
a Continuing Value of $17,299.8 million. 
When summing all the discounted cash flows with the Continuing Value, the firm becomes 
valued at $17,854.5 million. 
 
6.2.2.2. Weighted-Average Cost of Capital 
As referred above, the WACC includes several components and the ways to compute Incyte’s 
components was the same as for Amgen’s. 
The target’s cost of debt, based only on the loans since the bonds outstanding had a very short 
maturity, provided a rating of A (Thomson Reuters Eikon, 2018), inducing a spread of 1.04% 
over the 10-year Treasury bonds, which has a yield of 2.98%. Therefore, the cost of debt was 
assumed to be 4.02%. 
To derive the cost of equity, it was necessary to form a peer group, and the method used was 
the same as before: the cluster analysis. By collecting a sample of 16 companies and after testing 
for several clusters, it was found that Incyte always ended up with three other companies in its 
cluster: Vertex Pharmaceuticals, Alexion Pharmaceuticals, and Repligen Corporation. The 
levered betas of these companies were 1.2, 1.42, and 1.35, respectively, and they were used to 
compute their unlevered betas, by considering each firm’s capital structure. The average 
unlevered beta from the group was assumed to be Incyte’s unlevered beta, which was 0.86. 
Applying to the company’s Debt-to-Equity ratio of 1.47% and the beta of debt of 0.3, the value 
for the levered beta was 0.87. Using the same value of risk-free and market risk premium as 
used for Amgen, the cost of equity was determined to be 8.2%. 
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By applying the ratios of (Gross) Debt-to-Capital (1.5%) and Equity-to-Capital (98.5%), based 
on 2017’s values and using the same marginal tax rate as for Amgen (35.3%) the WACC was 
determined to be 8.2%. 
 
6.2.2.3. Equity Value 
After obtaining the Enterprise Value, it is necessary to include all the excess assets and subtract 
the values of debt. As a result, to get the target’s Equity Value, it was added $868.8 million of 
Excess Cash, $270.1 million of Excess Marketable Securities and was subtracted the Market 
Value of Debt ($53.6 million). The total value of Equity was then $18,939.8 million, which 
means each share is valued at $89.4. 
 
6.2.2.4. Sensitivity Analysis 
To understand how the valuation would be impacted if some of the inputs were changed, it was 
performed a sensitivity analysis (Exhibit 11.29. Incyte’s Sensitivity Analysis). 
If the WACC computed was underestimated and the return required by the capital providers 
was supposedly higher, the valuation would have been overestimated by around $6,000 million. 
If the company was supposed to grow the nominal growth rate for advanced economies in 
perpetuity (3.8%), that would have increased the valuation, but only for $722.6 million. 
However, if it was assumed that the company would have continued to grow at 7.4%, the 
valuation would have decreased to $15,753.0 million. 
If R&D Expenses were assumed to remain at the level of 2017 (93.8%), that would have a huge 
impact on the valuation, as it would decrease the enterprise value by $565,271.7 million. On 
the other hand, if it was assumed that these expenses would be at the industry level, the value 
of the company would increase by $233,664.6 million. 
 
6.2.3. Multiples 
With the peer group derived from the cluster analysis were computed three multiples and 
calculated the Enterprise and Equity values for Incyte (Exhibit 11.30. Incyte’s Multiples). Each 
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multiple is the average of the multiples for the three companies, and they were applied to 
Incyte’s data for 2016, as the values for EBITDA and EBIT of 2017 were negative. 
EV/EBITDA and EV/EBIT give close values, whereas the multiple EV/Revenues gives the 
highest value, with almost $6,000 million of difference to EV/EBIT. The main reason behind 
this difference may be related to the fact that Incyte’s EBITDA and EBIT are very small when 
compared to its revenues, as it registers high operating expenses. 
 
6.2.4.  Valuation Summary 
After getting all the possible values for Incyte, it is possible to conclude that EV/EBITDA and 
EV/EBIT give closer but low values and DCF model and EV/Revenues provide the highest 








However, when the Market Capitalization as of 01.02.2018 is introduced in the range of the 
possible Equity values, it is higher than any other value provided by the different approaches. 
The DFC model and the multiples EV/Revenues are the ones that give the closest value to the 






















Figure 7 - Valuation range of Incyte's Enterprise Value 
Figure 8 - Valuation rage of Incyte's Equity Value 
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7. Synergies 
The main reason behind M&A are the synergies, the added value that a merger or an acquisition 
brings to the newly combined firm. The synergies can be operational if they are related to the 
business itself, or financial if they are related to financial benefits arising from the combination 
of the two firms. 
 
7.1. Combined firm without synergies 
The first step in analysing synergies is to determine the value of the combined firm as if the 
transaction did not bring any benefits. The determination of this value would be the sum of the 
two companies to form a one combined firm, as a stand-alone business. 
For each of the statements (NOPLAT, Total Funds Invested and Free Cash Flow), the items of 
both firms were added to create a new value for the combined firm. The relevant statements for 
the combined firm are presented in the Exhibits 11.31. Combined Firm’s NOPLAT, 11.32. 
Combined Firm’s Net Income, 11.33. Combined Firm’s Invested Capital, 11.34. Combined 
Firm’s Equity and Debt, and 11.35. Combined Firm’s Free Cash-Flow Statement. 
Assuming the transaction is closed by the value of Incyte as of 01.02.2018 ($18,992.1 million), 
the newly combined firm would have an Enterprise Value of $137,875.4 million, which is just 
the sum of the value of the firms obtained through the DCF model. Adding the values of Excess 
Cash ($868.8 million) and Excess Marketable Securities ($22,520.1 million), already 
considering the value of the acquisition, and subtracting the Market Value of Debt ($39,350.4 
million), it is obtained the Equity Value of the combined firm, which is $121,913.9 million. 
This assumes that the transaction is fully paid in cash. 
 
7.2. Combined firm with synergies 
After getting the value of the combined firm, it is time to analyse the potential synergies derived 





Operational Synergies - Revenues Enhancements 
Incyte has presence in Europe since it acquired ARIAD Pharmaceuticals in 2016, so it has low 
experience in European operations, whereas Amgen already launched several products in 
Europe and has properties to develop, sell and manage its European operations. This 
knowledge, properties, and channels in the European market could be useful for Incyte and 
could enhance its future Revenues in Europe. For that reason, it was assumed that the combined 
firm would increase its sales by 0.5%, below than the average growth rate for advanced 
economies5. 
The combination of the two firms makes the new company stronger in terms of investing power. 
And as one of the objectives of the acquisition is to gain strong market power and face the rising 
competition, the new firm should increase the investment in research and development, to 
discover new drugs and increase future revenues. As a result, it was assumed that the company 
would increase the R&D Expenditures up to 35% of previous year’s Revenues, up from 19.5% 
of Revenues in 2018 This increase would occur in the first 5 years of the acquisition, and after 
that, R&D Expenditures would decrease to 25% of previous year’s Revenues. 
Nevertheless, the combined firm is also expected to increase efficiency in transforming these 
investments into improvements in sales. Therefore, Revenues are assumed to be related with 
the R&D Expenditures, such that Revenues will represent 142.3% of the increase in R&D, but 
only two years after these investments start to be realized. This percentage is based on Incyte’s 
historical data and the relation between these two variables. It implies that the investment in 
R&D will increase Revenues in more than what was invested previously. 
 
Operational Synergies – Costs Savings  
One of the main cost savings in M&A is the decrease in the number of employees after the 
transaction. The reason behind this strategy is that, when to companies are combined, some jobs 
will be duplicated, and does not make sense to continue to have the previous number of 
employees to do the same type of job. As a result, the employees were divided into executives, 
researchers and medical affairs, and administrative, sales and marketing. The data of the number 
of executives was taken from Reuters Eikon, and the number of researchers and administrative 
was based on the data about Incyte’s employees. As Amgen did not have any information 
                                                          
5 The advanced economies are expected to grow 3.8% (IMF, 2018) 
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regarding this categorization, the data from Incyte was applied to the acquirer. Incyte has 1,208 
employees, of which 16 are executives, 762 are researchers and 430 are administrative or belong 
to the sales and marketing division. This means that 63.1% of the employees are researchers 
and 35.6% are administrative. Applying this ratio to Amgen, it was derived that 13,373 
employees were researchers and 7,404 were administrative, being the remaining 23 executives. 
For the acquisition, no research or medical affairs employees were assumed to be fired, as they 
are essential for the process of discovering and developing new drugs. Therefore, the only 
category to suffer changes would be the administrative, sales and marketing. The reduction in 
the number of employees assumed was of 50%, which implies a reduction of $798.9 million in 
salaries and benefits in each year of the explicit period. 
However, when employees are fired, usually they must be paid an indemnity for being out of 
the company for the remaining years of their career. Therefore, if the present value of all future 
payments that needed to be done if the employees remained in the company is considered, there 
is an amount of $31,127.6 million to be recognized in 2019, since this is the year where 
employees will be dismissed from the company. 
The combination of two companies that use the same type of raw materials and products to 
develop drugs increases the power they have over suppliers. Therefore, it is expected that the 
costs of sales decrease by 3.5% once the two firms are combined. The decrease was based on a 
research that found out that the decrease in cost of sales due to increased power over suppliers 
represents, on average, 5 to 10% of the total cost savings in the combined firm (Tompkins, 
2012). The 3.5% decrease represents 8.9% of the costs saved due to the acquisition. 
Another typical synergy of transactions is the close and sale of facilities or properties that 
become unnecessary after the deal is closed. In this case, there is one facility that could be 
closed after the deal takes place. Incyte had a property in Geneva, Switzerland that can be closed 
after the transaction, since it has another property in the country (in Lausanne, where the 
European headquarters are) and Amgen has another two. Therefore, the item NPPE should be 
reduced by the value of the facility minus accumulated depreciation, which results in a decrease 
of $11.6 million.  
Incyte depends on 3rd parties to manufacture its products, but Amgen has facilities to 
manufacture its own products. By combining the two firms, Incyte could reduce its dependence 
on other firms by producing some products at Amgen’s facilities. This reduction should be 
smooth throughout the explicit period, as these are contracts that cannot be ended from one day 
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to the other. Therefore, if Incyte reduces the weight of these contracts from 59.5% to 29.5% of 
the SG&A costs, this would reduce these costs by $2,908.1 million until 2027, starting in 2019. 
It was not assumed a full reduction in these costs since Incyte intends to maintain some of these 
relationships in the future (Incyte Corporation, 2017). 
However, the closing of facilities and the increase in the use of others urges a higher investment 
in NPPE. It was assumed that after 2025, the investment in NPPE should be 3.4% of the increase 
in Revenues, as this was the ratio already verified between Capex and Revenues. 
Although there are some potential costs savings and revenues improvements, there is an 
expense that the combined firm will need to incur to make sure the acquisition is successful. 
After the transaction takes place, it is estimated that around $5,222.8 million will be spent in 
merging the companies, harmonizing methods of work and create a unique culture, which was 
included in the item Other Operating Expenses of the combined firm, in the years 2019 and 
2020, assuming the acquisition will be completed in 2018. A more detailed explanation about 
this expense is presented in chapter 9.  
In addition, there are other sources of synergies that are harder to quantify but may impact the 
business of the combined firm, such as the strong mechanism of Amgen to monitor customers 
and suppliers that could be applied to the whole business and decrease payments delayed and 
ensure the quality of the supplied material. Also, Amgen has strong marketing channels to sell 
its products, which could be used by Incyte and at the same time increase revenues and decrease 
costs.  
All other relevant items of the NOPLAT (Exhibit 11.37. Combined Firm’s NOPLAT after 
Synergies), Net Income (Exhibit 11.38. Combined Firm’s Net Income after Synergies), 
Invested Capital (Exhibit 11.39. Combined Firm’s Invested Capital after Synergies), and Equity 
and Debt (Exhibit 11.40. Combined Firm’s Equity and Debt after Synergies) are presented in 
chapter 10 – Appendices. Dividends were assumed to be zero in the first 5 years after the 
acquisition. After 2024, the previous year’s excess cash would be distributed to shareholders. 
 
Value of Synergies 
After introducing all the synergies and adjusting all the items of the statements, it was 
constructed the Free Cash-Flow Statement, from where it was obtained all the Free Cash-Flows 
of the combined firm after synergies and the Continuing Value (Exhibit 11.41. Combined 
35 
Firm’s Free Cash-Flow Statement after Synergies). The Continuing Value ($156,427.4 million) 
was computed with the formula presented previously, with a growth rate in perpetuity equal to 
the weighted average of the growth perpetuities of both companies (1.8%), RONIC of 10.8%, 
which is the average RONIC of the last 4 years and a WACC of 7.4%, computed using the 
values of the combined company. 
The value of the combined firm was determined to be $166,398.1 million, from which is 
possible to obtain the value of synergies, by subtracting the Enterprise Values of Amgen 
($120,020.8 million) and Incyte ($17,854.5 million). Synergies were valued at $28,522.8 
million. 
However, this value should be analysed carefully. It includes all the synergies arising from the 
combination, which implies that synergies that are harder or less likely to be achieved are also 
being considered. But for a matter of determination of the price of the acquisition, it should be 
considered the value of synergies that have a higher probability of being realized.  
 
Effects of the acquisition 
Exhibit 11.42. Operating and Financial Rations before and after Synergies compares the 
combined firm with and without synergies. It is possible to conclude that the acquisition would 
increase the average growth rate of Revenues and of the Free Cash-Flow and would increase 
the investment in R&D. Although Operating Expenses are assumed to increase with the 
acquisition, which decreases the average EBITDA Margin to 30.8%, the Net Income Margin 
would suffer only a very slight decrease, from 22.8% to 21.3%, when the first years of the 
acquisition are excluded. Excluding 2019 and 2020, EBITDA/Interest Expense ratio improves 
slightly, and Debt/EBITDA ratio decreases, even though the increase in Debt/Total Funds 
Invested. This means that the combined firm would be capable of generating enough EBITDA 
to compensate the increase in Debt and, consequently, in Interest Expense. Regarding ROE, 
considering the whole period, the return would decrease drastically. However, if only the last 8 
years are considered, shareholders seem to be better off with the acquisition. When it comes to 
ROIC and RONIC, if the whole period is considered, the returns decrease with the introduction 
of synergies. However, when the ratios are computed with data from 2020 onwards, the ROIC 




7.3. Sensitivity Analysis 
It is also helpful to understand what would happen if certain assumptions were changed 
regarding the effect of synergies (Exhibit 11.43. Synergies’ Sensitivity Analysis). 
If the increase in Revenues regarding the stronger position in Europe was assumed to be equal 
to the nominal growth rate of advanced economies (3.8%) that would have increased the value 
of the synergies in $21,266.6 million. 
If the increase in Revenues derived from the increase in investment in R&D would just equal 
the investment made, that would decrease the value by $4,106.3 million. 
If the decrease in administrative employees was higher, that would increase the value of 
synergies to $27,089.9 million, which is not a huge difference from the current value of 
synergies. A higher decrease in employees would decrease the value to pay to employees in 
salaries, but it would increase the indemnity to pay to dismissed employees. 
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8. The Transaction 
Value of the Acquisition 
For the transaction, it is assumed that Amgen would buy all the shares outstanding of Incyte, to 
own 100% of the company., which translates into 211.8 million shares. 
Although valuations were performed to understand what the correct value of the firm would be, 
Amgen will have to pay at least the current market value of Incyte ($18,992.1 million, or $89.7 
per share). But since synergies arising from the combination were calculated, Amgen can pay 
more than the current market value, because, for the acquirer, the acquisition of Incyte seems 
to bring several benefits. This premium over the current market value may also ensure that 
current shareholders accept to sell their shares to Amgen. 
Considering previous acquisitions, Amgen paid, on average, a premium of 37.5%. Assuming 
the company wants to maintain the same premium in this acquisition, it would pay $26,114.15 
million for the full control of the target and Incyte’s shareholders would then receive $123.3 
per share sold. This value will be considered as the deal value this point onwards. 
In addition, it is necessary to define beforehand a walk-away price, which is defined by the 
maximum value the company is willing to pay for the acquisition. It is assumed that the 
maximum premium of the acquisition would be $35,731.3 million, corresponding to a value of 
synergies of $16,739.2 million, that includes the present value of all the costs savings 
($10,026.6 million), which they are the easiest to achieve, and of the revenues enhancements 
that are more likely to be achieved ($6,712.6 million). The revenues that are more likely to be 
achieved were assumed to arise from the increased investing power of the combined firm and 
its effect on revenues. It was assumed that it would be more likely the company to be able to 
increase revenues in the same amount as the investment made. 
Every acquisition is expected to generate expenses before the transaction is made. These 
expenses are mainly related to due diligence activity, which is a strategy that acquirers perform 
to obtain the largest amount of information on the target before the acquisition takes place. On 
the previous acquisition of Amgen (Onyx Pharmaceuticals in 2013), it spent 3.7% of the deal 
value on transaction-related expenses. Based on this, it is expected that Amgen spends $966.22 





As shown by research, hostile transactions result in higher returns for the target’s shareholders, 
however, and as explained in chapter 9, both firms will work together to create a new culture 
and methods of work that can be applied to both companies. Therefore, if Amgen approaches 
directly Incyte’s shareholders, avoiding discussing this acquisition with the management, the 
integration of the firms will be harder if the deal is closed. As a result, and although the returns 
could be lower, it will be assumed that Amgen will approach Incyte in a friendly way. 
 
Method of Payment 
At the end of the fiscal year of 2017, Amgen had $41,242.1 million in Excess Cash and Excess 
Marketable Securities. This large amount of assets is one of the reasons Amgen wants to acquire 
a new company, as this provides a large financial flexibility. For this reason, the Incyte 
acquisition can be financed by a large amount of excess cash and securities, with no need to 
issue new debt. 
The amount of the acquisition was determined to be $26,114.15 million, which allows Amgen 
to spend 63.3% of the amount and remain with $15,128.0 million on its balance sheet. 
The method of payment is in accordance with the previously discussed literature, that argues 
that all-cash deals tend to provide positive returns to all shareholders involved. In addition, all 
previous acquisitions made by the acquirer have been paid only in cash, meaning the company 
has a clear preference for the method of payment of its acquisitions. 
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9. Post-Merger Integration  
It is necessary to define beforehand the plan to apply after the deal takes place (Bruner, Applied 
Mergers & Acquisitions, 2004). This plan can be designed once the due diligence gives enough 
information about the target company. However, not all information can be acquired in the due 
diligence process, which means that after the acquisition, Amgen can be faced with new 
information. 
In addition, it is necessary to understand the type of relationship that the acquisition will create 
between the two companies, as this defines the newly combined firm. In this specific case, the 
companies will have a mix of autonomy and interdependence, since they remain with the power 
over the decision-making process, and both brands and products will remain the same. 
However, and to promote a cohesive environment after the acquisition, the cultures of the 
companies should be merged to form one unique culture that fit both work environments.  
If changes are needed to be made, they will represent an expense for the newly combined firm. 
Research shows that, on average, companies spend 14% of the deal value on the integration 
phase (EY, 2014). However, managers argue they should have made a higher investment, as 
this is an extremely important phase of the whole process. As a result, it will be assumed that 
these expenses will represent 20% of the value of the deal ($5,222.8million), to ensure that all 
necessary changes are implemented. Also, it should be put the hypothesis of a second wave of 




Amgen is currently looking for a target in its industry to pursue an acquisition. It has the 
financial flexibility to do so, and it needs a solution for the weak results of 2017 and the not 
very optimistic forecasts for its revenues. Incyte is a biotechnology company, whose earnings 
have not been positive, but the high investments it has been making in R&D promise future 
high growth rates fulfilling the needs of growth of Amgen. 
This acquisition is assumed to create an interdependent relationship, where Incyte can adopt 
the strengths of Amgen in the drug development process and become more efficient in 
transforming investment into revenues. On the other hand, Amgen can offset the poor 
performance by buying someone else’s growth and take advantage of economies of scale to 
decrease costs with supplied material and employees. The combined firm would put together 
knowledge, expertise, and resources, which could guarantee an increase in investing power in 
R&D and a consequent increase in revenues.  
Assuming a premium of 37.5%, Amgen would offer $26,114.15 million for the full control of 
the company, which values each share at $123.3. Incyte’s shareholders would then have a gain 
of $33.6 for each share sold if this price is accepted. This price also ensures the creation of 
value for all the future shareholders of the combined firm.  
The acquisition is also expected to increase Revenues and FCF growth rates that are capable to 
offset the decrease of EBITDA and Net Income margins, caused by the increase in operating 
expenses. Returns for shareholders seem to be improved, which is a positive aspect for Amgen, 
who was concerned about the returns of its shareholders. 
PMI could become less difficult through a high investment in the due-diligence process, to get 
to know better what is expected from Incyte after the deal is closed. This investment would 
allow the phase of integration to occur smoothly, when putting together employees, methods of 











2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Revenues 14,268.0 14,771.0 15,003.0 14,642.0 15,053.0 15,582.0 17,265.0 18,676.0 20,063.0 21,662.0 22,991.0 22,849.0 
 Product Sales 13,858.0 14,311.0 14,687.0 14,351.0 14,660.0 15,295.0 16,639.0 18,192.0 19,327.0 20,944.0 21,892.0 21,795.0 
 ENBREL 2,879.0     3,230.0     3,598.0     3,493.0     3,534.0     3,701.0     4,236.0     4,551.0     4,688.0     5,364.0     5,965.0     5,433.0     
      % of Revenues 20.2% 21.9% 24.0% 23.9% 23.5% 23.8% 24.5% 24.4% 23.4% 24.8% 25.9% 23.8%
 Neulasta 2,710.0     3,000.0     3,318.0     3,355.0     3,558.0     3,952.0     4,092.0     4,392.0     4,596.0     4,715.0     4,648.0     4,534.0     
      % of Revenues 0.2          0.2          0.2          22.9% 23.6% 25.4% 23.7% 23.5% 22.9% 21.8% 20.2% 19.8%
 Aranesp 4,121.0     3,614.0     3,137.0     2,652.0     2,486.0     2,303.0     2,040.0     1,911.0     1,930.0     1,951.0     2,093.0     2,053.0     
      % of Revenues 28.9% 24.5% 20.9% 18.1% 16.5% 14.8% 11.8% 10.2% 9.6% 9.0% 9.1% 9.0%
 Prolia 33.0         203.0       472.0       744.0       1,030.0     1,312.0     1,635.0     1,968.0     
      % of Revenues 0.2% 1.3% 2.7% 4.0% 5.1% 6.1% 7.1% 8.6%
 Sensipar/Mimpara 321.0       463.0       597.0       651.0       714.0       808.0       950.0       1,089.0     1,158.0     1,415.0     1,582.0     1,718.0     
      % of Revenues 2.2% 3.1% 4.0% 4.4% 4.7% 5.2% 5.5% 5.8% 5.8% 6.5% 6.9% 7.5%
 XGEVA 8.0           351.0       748.0       1,019.0     1,221.0     1,405.0     1,529.0     1,575.0     
      % of Revenues 0.1% 2.3% 4.3% 5.5% 6.1% 6.5% 6.7% 6.9%
 EPOGEN 2,511.0     2,489.0     2,456.0     2,569.0     2,524.0     2,040.0     1,941.0     1,953.0     2,031.0     1,856.0     1,282.0     1,096.0     
      % of Revenues 17.6% 16.9% 16.4% 17.5% 16.8% 13.1% 11.2% 10.5% 10.1% 8.6% 5.6% 4.8%
NEUPOGEN 1,213.0     1,277.0     1,341.0     1,288.0     1,286.0     1,260.0     1,260.0     1,398.0     1,159.0     1,049.0     765.0       549.0       
      % of Revenues 8.5% 9.0% 9.4% 9.0% 9.0% 8.8% 8.8% 9.8% 8.1% 7.4% 5.4% 3.8%
 Other Products 103.0       238.0       240.0       343.0       517.0       677.0       900.0       1,135.0     1,514.0     1,877.0     2,393.0     2,869.0     
      % of Revenues 0.7% 1.6% 1.6% 2.3% 3.4% 4.3% 5.2% 6.1% 7.5% 8.7% 10.4% 12.6%
 Other Revenues 410.0      460.0      316.0      291.0      393.0      287.0      626.0      484.0      736.0      718.0      1,099.0   1,054.0   
      % of Revenues 2.9% 3.1% 2.1% 2.0% 2.6% 1.8% 3.6% 2.6% 3.7% 3.3% 4.8% 4.6%
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11.2. Amgen’s Historical NOPLAT 
 
11.3. Amgen’s Historical Net Income 
 
NOPLAT - $M
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Revenues 14,268.0 14,771.0 15,003.0 14,642.0 15,053.0 15,582.0 17,265.0 18,676.0 20,063.0 21,662.0 22,991.0 22,849.0 
Operating expenses 9,511.0   9,589.0   8,716.0   8,087.0   8,491.0   10,211.0 10,602.0 11,523.0 11,780.0 11,065.0 11,078.0 10,921.0 
      % of Revenues 66.7% 64.9% 58.1% 55.2% 56.4% 65.5% 61.4% 61.7% 58.7% 51.1% 48.2% 47.8%
  Cost of Sales 2,095.0   2,548.0   2,296.0   2,091.0   2,220.0   2,708.0   3,199.0   3,346.0   4,422.0   4,227.0   4,162.0   4,069.0   
      (-) Depreciation and Amortization 917.0-      1,202.0-   1,073.0-   1,049.0-   1,017.0-   1,059.0-   1,086.0-   1,286.0-   2,092.0-   2,127.0-   2,119.0-   1,955.0-   
  Research and Development (R&D) 3,366.0   3,266.0   3,030.0   2,864.0   2,894.0   3,167.0   3,380.0   4,083.0   4,297.0   4,070.0   3,840.0   3,562.0   
  Selling, general and administrative 3,366.0   3,361.0   3,789.0   3,820.0   3,983.0   4,499.0   4,814.0   5,184.0   4,699.0   4,846.0   5,062.0   4,870.0   
  Other operating expenses 1,601.0   1,616.0   674.0      361.0      411.0      896.0      295.0      196.0      454.0      49.0        133.0      375.0      
EBITDA 4,757.0   5,182.0   6,287.0   6,555.0   6,562.0   5,371.0   6,663.0   7,153.0   8,283.0   10,597.0 11,913.0 11,928.0 
      % of Revenues 33.3% 35.1% 41.9% 44.8% 43.6% 34.5% 38.6% 38.3% 41.3% 48.9% 51.8% 52.2%
Depreciation 547.0       786.0       648.0       624.0       594.0       679.0       689.0       644.0       716.0       727.0       619.0       655.0       
Amortization 370.0       416.0       425.0       425.0       423.0       380.0       397.0       642.0       1,376.0     1,400.0     1,500.0     1,300.0     
EBIT 3,840.0   3,980.0   5,214.0   5,506.0   5,545.0   4,312.0   5,577.0   5,867.0   6,191.0   8,470.0   9,794.0   9,973.0   
      % of Revenues 26.9% 26.9% 34.8% 37.6% 36.8% 27.7% 32.3% 31.4% 30.9% 39.1% 42.6% 43.6%
Operating cash taxes 965.2       1,283.4     915.8       1,304.7     1,338.3     780.3       1,220.0     4,531.9     1,339.5     742.4       5,102.3     7,835.5     
NOPLAT 2,874.8   2,696.6   4,298.2   4,201.3   4,206.7   3,531.7   4,357.0   1,335.1   4,851.5   7,727.6   4,691.7   2,137.5   
NET INCOME - $M
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
NOPLAT 2,874.8   2,696.6   4,298.2   4,201.3   4,206.7   3,531.7   4,357.0   1,335.1   4,851.5   7,727.6   4,691.7   2,137.5   
Decrease (increase) in operating 
deferred taxes -          113.0       480.0-       -          -          -          -          3,498.0     37.0-         1,222.0-     2,616.0     5,410.0     
Interest expense, net -129.0 -496.0 -551.0 -578.0 -604.0 -610.0 -1,053.0 -1,022.0 -1,061.0 -1,079.0 -1,260.0 -1,304.0
Interest and other income, net 309.0 309.0 352.0 221.0 328.0 449.0 466.0 405.0 465.0 603.0 685.0 904.0
Foreign currency contracts 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -56.0 24.0
Foreign currency gain 0.0 0.0 0.0 27.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Ineffective gain/loss Hedging Derivative 0.0 0.0 0.0 0.0 0.0 -1.0 19.0 15.0 -10.0 -16.0 0.0 0.0
Gain on sale of Investment 0.0 0.0 0.0 28.0 48.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Non-Recurring Tax Change 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -6,100.0
Nonoperating taxes -104.8 455.4 432.8 705.7 648.3 313.3 556.0 849.9 949.5 925.4 1,045.3 907.5
Net Income 2,950.0 3,078.0 4,052.0 4,605.0 4,627.0 3,683.0 4,345.0 5,081.0 5,158.0 6,939.0 7,722.0 1,979.0
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INVESTED CAPITAL - $M
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Operating Current Assets 5,712.2 6,176.2 5,962.7 5,777.0 6,000.2 7,257.9 7,479.8 8,329.8 8,069.5 7,551.9 8,362.8 8,233.9
(-) Operating Current Liabilities 5,144.0 4,179.0 3,886.0 3,873.0 4,082.0 5,670.0 5,340.0 4,979.0 5,903.0 6,416.0 5,952.0 7,052.0
Total Operating Working Capital 568.2 1,997.2 2,076.7 1,904.0 1,918.2 1,587.9 2,139.8 3,350.8 2,166.5 1,135.9 2,410.8 1,181.9
(+) Net Property, Plant and Equipment 5,921.0 5,941.0 5,879.0 5,738.0 5,522.0 5,420.0 5,326.0 5,349.0 5,223.0 4,907.0 4,961.0 4,989.0
(+) Other Operating Assets, net of Other Liabilities 564.0 -141.0 -1,660.0 -1,737.0 -1,204.0 -1,620.0 -1,926.0 -1,171.0 -1,351.0 -1,635.0 -619.0 510.0
(+) Net Intangible Assets 3,747.0 3,332.0 2,988.0 2,567.0 2,230.0 2,584.0 3,968.0 13,262.0 12,693.0 11,641.0 10,279.0 8,609.0
Invested Capital (Excluding Goodwill) 10,800.2 11,129.2 9,283.7 8,472.0 8,466.2 7,971.9 9,507.8 20,790.8 18,731.5 16,048.9 17,031.8 15,289.9
(+) Goodwill 11,302.0    11,240.0    11,339.0    11,335.0    11,334.0    11,750.0    12,662.0    14,968.0    14,788.0    14,787.0    14,751.0    14,761.0    
Invested Capital (Including Goodwill) 22,102.2 22,369.2 20,622.7 19,807.0 19,800.2 19,721.9 22,169.8 35,758.8 33,519.5 30,835.9 31,782.8 30,050.9
(+) Excess Cash 1,005.8 1,737.8 1,480.3 2,597.0 2,993.8 6,640.1 2,924.2 3,441.2 3,344.5 3,725.1 2,803.2 3,364.1
(+) Excess Marketable Securities 4,994.0      5,127.0      7,778.0      10,558.0    14,135.0    13,695.0    20,804.0    15,596.0    23,295.0    27,238.0    34,844.0    37,878.0    
(+) Other Non Operating Assets, net of Other Non 
Operating Liabilities 241.0        292.0        356.0        306.0        377.0        400.0        46.0          3,386.0      396.0        48.0-          745.0        371.0        
Total Funds Invested 28,343.0 29,526.0 30,237.0 33,268.0 37,306.0 40,457.0 45,944.0 58,182.0 60,555.0 61,751.0 70,175.0 71,664.0
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EQUITY AND DEBT - $M
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Equity
  Common stock and additional paid-in capital 24,155.0  24,976.0  26,441.0  26,944.0  27,299.0  27,777.0  29,337.0  29,891.0  30,410.0  30,649.0  30,784.0  30,992.0  
  Accumulated deficit 5,203.0-    7,160.0-    5,673.0-    4,322.0-    3,508.0-    8,919.0-    10,423.0-  7,634.0-    4,624.0-    2,086.0-    438.0-       5,072.0-    
  Other -          -          -          -          -          -          14.0-         17.0-         15.0-         6.0-           5.0-           -          
  Accumulated other comprehensive income 12.0         53.0         117.0       8.0-           7.0-           13.0-         -          -          -          -          -          -          
  Foreign Currency Translation Reserve -          -          -          40.0         22.0         21.0         12.0         68.0-         264.0-       511.0-       610.0-       529.0-       
  Cash Flow Hedges -          -          -          82.0-         3.0           43.0         35.0-         33.0-         290.0       297.0       282.0       6.0-           
  Available for Sale Securities -          -          -          95.0         135.0       120.0       183.0       43.0-         19.0-         260.0-       138.0-       144.0-       
Deferred tax liabilities, net of deferred tax assets 367 480 0 0 0 0 0 3,498 3,461 2,239 4,855 10,265
Dividends payable -           -           -           -           -           -           355.0        460.0        601.0        -           849.0        816.0        
Adjusted Equity 19,331.0  18,349.0  20,885.0  22,667.0  23,944.0  19,029.0  19,415.0  26,054.0  29,840.0  30,322.0  35,579.0  36,322.0  
Debt 
Short-term Debt 1,798.0 2,000.0 1,000.0 0.0 2,488.0 84.0 2,495.0 2,505.0 500.0 2,247.0 4,403.0 1,152.0
  Curr. Port. Conv. Note 1,698.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
  Short-term borrowings and current portion 100.0 2,000.0 1,000.0 0.0 2,488.0 84.0 2,495.0 2,505.0 500.0 2,247.0 4,403.0 1,152.0
Long-term Debt 7,214.0 9,177.0 8,352.0 10,601.0 10,874.0 21,344.0 24,034.0 29,623.0 30,215.0 29,182.0 30,193.0 34,190.0
  Convertible notes 5,080.0 5,080.0 4,257.0 4,512.0 2,296.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
  Long-term debt 2,134.0 4,097.0 4,095.0 6,089.0 8,578.0 21,344.0 24,034.0 29,623.0 30,215.0 29,182.0 30,193.0 34,190.0
Total Debt 9,012.0 11,177.0 9,352.0 10,601.0 13,362.0 21,428.0 26,529.0 32,128.0 30,715.0 31,429.0 34,596.0 35,342.0
Total Funds Invested 28,343.0 29,526.0 30,237.0 33,268.0 37,306.0 40,457.0 45,944.0 58,182.0 60,555.0 61,751.0 70,175.0 71,664.0
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11.6. Amgen’s Historical Free Cash-Flow Statement  
 
 




FREE CASH-FLOW STATEMENT - $M
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
NOPLAT 2,696.6 4,298.2 4,201.3 4,206.7 3,531.7 4,357.0 1,335.1 4,851.5 7,727.6 4,691.7 2,137.5
(+) Depreciation 786.0     648.0     624.0     594.0     679.0     689.0     644.0       716.0     727.0     619.0     655.0     
(+) Amortization 416.0     425.0     425.0     423.0     380.0     397.0     642.0       1,376.0   1,400.0   1,500.0   1,300.0   
Gross Cash-Flow 3,898.6 5,371.2 5,250.3 5,223.7 4,590.7 5,443.0 2,621.1 6,943.5 9,854.6 6,810.7 4,092.5
Investment in Operating Working Capital 1,429.1   79.5       172.7-     14.2       330.3-     551.9     1,211.1     1,184.3-   1,030.7-   1,275.0   1,228.9-   
Capital Expenditures 806.0     586.0     483.0     378.0     577.0     595.0     667.0       590.0     411.0     673.0     683.0     
Investment in Other Operating Assets, net 
of Other Liabilities 705.0-     1,519.0-   77.0-       533.0     416.0-     306.0-     755.0       180.0-     284.0-     1,016.0   1,129.0   
Investment in Intangible Assets 1.0         81.0       4.0         86.0       734.0     1,781.0   9,936.0     807.0     348.0     138.0     370.0-     
Investment in Goodwill 62.0-       99.0       4.0-         1.0-         416.0     912.0     2,306.0     180.0-     1.0-         36.0-       10.0       
Gross Investment 1,469.1 673.5-    233.3    1,010.2 980.7    3,533.9 14,875.1 147.3-    556.7-    3,066.0 223.1    
Free Cash-Flow 2,429.6 6,044.7 5,017.0 4,213.5 3,610.0 1,909.2 -12,254.0 7,090.8 10,411.3 3,744.7 3,869.4
FINANCIAL RATIOS (%)
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
EBITDA /Interest Expenses (x) 36.9 10.4 11.4 11.3 10.9 8.8 6.3 7.0 7.8 9.8 9.5 9.1
Debt/EBITDA (x) 1.9 2.2 1.5 1.6 2.0 4.0 4.0 4.5 3.7 3.0 2.9 3.0
Debt/Total Funds Invested 31.8% 37.9% 30.9% 31.9% 35.8% 53.0% 57.7% 55.2% 50.7% 50.9% 49.3% 49.3%
Equity/Total Funds Invested 68.2% 62.1% 69.1% 68.1% 64.2% 47.0% 42.3% 44.8% 49.3% 49.1% 50.7% 50.7%
ROE 15.6% 17.2% 19.4% 20.3% 19.3% 19.4% 22.8% 23.0% 20.0% 24.7% 25.8% 7.8%
ROIC without Goodwill 26.6% 24.2% 46.3% 49.6% 49.7% 44.3% 45.8% 6.4% 25.9% 48.2% 27.5% 14.0%
ROIC with Goodwill 13.0% 12.1% 20.8% 21.2% 21.2% 17.9% 19.7% 3.7% 14.5% 25.1% 14.8% 7.1%
RONIC without Goodwill -54.1% -86.8% 11.9% -93.6% 136.6% 53.7% -26.8% -170.8% -107.2% -308.9% 146.6%
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2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Revenues 27.6      34.4      3.9        9.3        169.9    94.5      297.1    354.9    511.5    753.8    1,105.7 1,536.2 
 Product Revenues -        -        -        -        -        2.0        136.0    235.4    357.6    601.0    882.4    1,200.3 
% of Revenues 0.0% 0.0% 0.0% 0.0% 0.0% 2.1% 45.8% 66.3% 69.9% 79.7% 79.8% 78.1%
JAKAFI -        -        -        -        -        2.0        136.0     235.4 357.6 601.0     852.8     1,133.4  
% of Revenues 100.0% 100.0% 100.0% 100.0% 100.0% 96.6% 94.4%
ICLUSIG -        -        -        -        -        -        -        -        -        -        29.6       66.9       
% of Revenues 3.4% 5.6%
 Product royalty revenues -        -        -        -        -        -        3.7        28.3      49.0      74.8      110.7    160.8    
% of Revenues 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.2% 8.0% 9.6% 9.9% 10.0% 10.5%
 Other revenues 3.4        4.6        3.3        3.5        0.9        0.5        0.5        0.2        0.1        0.1        0.1        0.1        
% of Revenues 12.3% 13.4% 84.6% 37.6% 0.5% 0.5% 0.2% 0.1% 0.0% 0.0% 0.0% 0.0%
 Milestone and contract revenues 24.2      29.9      0.7        5.8        168.9    91.9      156.9    91.0      104.9    77.9      112.5    175.0    
% of Revenues 87.7% 86.9% 17.9% 62.4% 99.4% 97.2% 52.8% 25.6% 20.5% 10.3% 10.2% 11.4%
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11.9. Incyte’s Historical NOPLAT 
 
 
11.10. Incyte’s Historical Net Income  
 
NOPLAT - $M
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Revenues 27.6      34.4      3.9          9.3          169.9    94.5      297.1    354.9    511.5    753.8    1,105.7 1,536.2  
Operating expenses 98.9      114.7    159.8      185.0      156.6    233.2    296.0    389.0    474.9    691.8    934.0    1,733.9  
      % of Revenues 358.3% 333.4% 4097.4% 1989.2% 92.2% 246.8% 99.6% 109.6% 92.8% 91.8% 84.5% 112.9%
Cost of Sales -        -        -         -         -        -        0.2        0.6        3.0        27.0      45.6      58.0       
      (-) Depreciation and Amortization 5.6-        5.0-        3.5-         4.0-         3.2-        4.4-        -        29.2-      41.4-      11.3-      26.8-      46.1-       
  Research and Development (R&D) 87.6      104.9    146.4     119.4     123.9    178.7    210.4    260.4    221.1    330.4    384.2    1,037.6  
  Selling, general and administrative 14.0      15.2      17.1       27.6       32.3      58.2      85.4      109.9    292.2    345.7    501.0    655.2     
  Other operating expenses 2.9        0.4-        0.2-         42.0       3.6        0.7        -        47.3      -        -        30.0      29.2       
EBITDA 71.3-      80.3-      155.9-      175.7-      13.3      138.7-    1.1        34.1-      36.6      62.0      171.7    197.7-     
      % of Revenues -258.3% -233.4% -3997.4% -1889.2% 7.8% -146.8% 0.4% -9.6% 7.2% 8.2% 15.5% -12.9%
Depreciation 3.3         3.1         1.8          1.4          1.1         2.2         -         29.2       41.4       11.3       14.2       24.6        
Amortization 2.3         1.9         1.7          2.6          2.1         2.2         -         -         -         -         12.6       21.5        
EBIT 76.90-    85.30-    159.40-    179.70-    10.10    143.10-  1.10      63.30-    4.80-      50.70    144.90  243.80-   
      % of Revenues -278.6% -248.0% -4087.2% -1932.3% 5.9% -151.4% 0.4% -17.8% -0.9% 6.7% 13.1% -15.9%
Operating cash taxes -         -         -          -          -         -         0.2         0.3         0.1-         1.0         3.2         0.9          
NOPLAT 76.9-      85.3-      159.4-      179.7-      10.1      143.1-    0.9        63.6-      4.7-        49.7      141.7    244.7-     
NET INCOME - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
NOPLAT 5,753.6   5,704.0   5,879.0   6,073.2   6,336.4   6,426.9   6,510.2   6,594.5   6,679.8   6,766.2   
Interest expense, net -1,332.1 -1,262.6 -1,259.1 -1,282.4 -1,307.6 -1,352.0 -1,368.6 -1,385.3 -1,402.3 -1,419.4
Interest and other income, net 990.3 772.1 855.1 916.7 922.1 938.1 942.9 955.4 971.0 983.4
Non-operating income -16.0 -16.0 -16.3 -16.6 -17.2 -17.4 -17.6 -17.8 -18.0 -18.3
Nonoperating taxes -120.7 -173.2 -142.6 -129.1 -136.1 -146.1 -150.3 -56.8 -56.8 -56.8
Net Income 5,275.1   5,024.2   5,316.1   5,561.8   5,797.8   5,849.5   5,916.6   6,089.9   6,173.7   6,255.1   
Net Income Margin 23.3% 22.2% 23.1% 23.7% 23.9% 23.8% 23.8% 24.2% 24.2% 24.3%
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INVESTED CAPITAL - $M
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Operating Current Assets 9.8 8.7 7.6 166.8 15.7 15.8 87.1 52.5 89.0 149.2 207.8 365.9
(-) Operating Current Liabilities 39.7 26.3 40.0 118.8 108.2 130.9 131.4 106.2 134.1 167.2 253.2 341.2
Total operating working capital -29.9 -17.6 -32.4 48.0 -92.5 -115.1 -44.3 -53.7 -45.1 -18.0 -45.4 24.7
(+) Net Property, Plant and Eequipment 5.9 4.0 2.8 1.8 4.9 6.5 6.3 26.8 81.7 86.0 167.6 259.8
(+) Other Operating Assets, net of Other Liabilities -18.0 -12.1 -6.6 -238.8 -171.2 -100.8 -29.7 -17.4 -46.0 16.7 37.1 124.8
(+) Net Intangible Assets -5.2 -7.1 -8.7 -11.4 -4.6 -4.7 -6.8 -2.3 0.0 0.0 270.4 236.9
Invested Capital (Excluding Goodwill) -47.2 -32.8 -44.9 -200.4 -263.4 -214.1 -74.5 -46.6 -9.4 84.7 429.7 646.2
(+) Goodwill -        -         -         -         -         -         -         -         -         -         155.6      155.6      
Invested Capital (Including Goodwill) -47.2 -32.8 -44.9 -200.4 -263.4 -214.1 -74.5 -46.6 -9.4 84.7 585.3 801.8
(+) Excess Cash 18.3 108.2 178.7 449.6 414.5 271.3 218.2 464.3 442.1 506.3 630.2 868.8
(+) Excess Marketable Securities 310.9     148.5      39.1        24.1        6.3          4.4          4.4          37.6        148.0      186.3      156.2      270.1      
(+) Other Non Operating Assets, net of Other Non 
Operating Liabilities 8.9         8.6          8.0          74.5        52.2        32.2        12.9        34.8        14.5        14.5        300.1-      286.1-      
Total Funds Invested 290.9 232.5 180.9 347.8 209.6 93.8 161.0 490.1 595.2 791.8 1,071.6 1,654.6
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EQUITY AND DEBT - $M
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Equity
  Common stock 0.1        0.1         0.1         0.1         0.1         0.1         0.1         0.2         0.2         0.2         0.2         0.2         
  Additional paid-in capital 828.9    841.3     961.2     1,288.0  1,332.3  1,380.7  1,476.9  1,541.8  1,701.9  1,950.8  2,096.9  3,627.4  
  Accumulated deficit 913.5-    1,000.4-  1,179.3-  1,391.2-  1,423.0-  1,609.6-  1,653.9-  1,737.0-  1,785.5-  1,779.0-  1,674.8-  1,990.0-  
  Accumulated other comprehensive loss 0.4-        0.5-         2.7-         0.7         2.0         1.6         1.9         2.0         1.8         0.8-         2.9-         7.0-         
Adjusted Equity 84.9-      159.5-     220.7-     102.4-     88.6-       227.2-     175.0-     193.0-     81.6-       171.2     419.4     1,630.6  
Debt 
Short-term Debt 4.7 5.3 5.3 7.1 4.8 4.8 4.8 1.9 87.0 0.8 0.8 7.4
  Convertible senior notes 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 85.2 0.0 0.0 7.4
  Interest Payable 4.7 5.3 5.3 7.1 4.8 4.8 4.8 1.9 1.8 0.8 0.8 0.0
Long-term Debt 371.1 386.6 396.2 443.2 293.4 316.2 331.0 681.5 590.0 619.9 651.5 16.6
  Convertible subordinated notes 257.1 264.4 265.2 135.1 17.0 18.0 9.0 0.0 0.0 0.0 0.0 0.0
  Convertible senior notes 114.0 122.2 131.0 308.1 276.4 298.2 322.0 661.6 590.0 619.9 651.5 16.6
Total Debt 375.8 391.9 401.5 450.3 298.2 321.0 335.8 683.4 677.0 620.7 652.3 24.0
Total Funds Invested 290.9 232.4 180.8 347.9 209.6 93.8 160.8 490.4 595.4 791.9 1,071.7 1,654.6
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11.13. Incyte’s Historical Free Cash-Flow Statement 
 
 
11.14. Incyte’s Historical Financial Ratios 
 
 
FREE CASH-FLOW STATEMENT -$M
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
NOPLAT -85.3 -159.4 -179.7 10.1 -143.1 0.9 -63.6 -4.7 49.7 141.7 -244.7
(+) Depreciation 3.1    1.8    1.4      1.1     2.2    -     29.2   41.4    11.3    14.2    24.6    
(+) Amortization 1.9    1.7    2.6      2.1     2.2    -     -    -     -     12.6    21.5    
Gross Cash-Flow -80.3 -155.9 -175.7 13.3 -138.7 0.9 -34.4 36.7 61.0 168.5 -198.6
Investment in Operating Working Capital 12.3   14.8-   80.4    140.5- 22.6-   70.9    9.4-    8.6      27.0    27.4-    70.1    
Capital Expenditures 4.3    2.4    1.8      5.3     6.0    0.2-      78.9   137.7  26.9    110.0  141.4  
Investment in Other Operating Assets, net of 
Other Liabilities 5.9    5.5    232.2-  67.6   70.4   71.1    12.3   28.6-    62.7    20.4    87.7    
Investment in Intangible Assets -    0.1    0.1-      8.9     2.1    2.1-      4.5    2.3      -     283.0  12.0-    
Investment in Goodwill -    -    -     -    -    -     -    -     -     155.6  -     
Gross Investment 22.5  6.8-    150.1- 58.7-  55.9  139.7 86.3  120.0 116.6 541.6 287.2 
Free Cash-Flow -102.8 -149.1 -25.6 72.0 -194.6 -138.8 -120.7 -83.3 -55.6 -373.1 -485.8
FINANCIAL RATIOS (%)
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
EBITDA /Interest Expenses (x) -4.0 -3.3 -6.3 -5.5 0.3 -3.2 0.0 -0.9 0.8 1.4 4.4 -28.7
Debt/EBITDA (x) -5.3 -4.9 -2.6 -2.6 22.4 -2.3 305.3 -20.0 18.5 10.0 3.8 -0.1
Debt/Total Funds Invested 129.2% 168.6% 222.1% 129.4% 142.3% 342.2% 208.8% 139.4% 113.7% 78.4% 60.9% 1.5%
Equity/Total Funds Invested -29.2% -68.6% -122.1% -29.4% -42.3% -242.2% -108.8% -39.4% -13.7% 21.6% 39.1% 98.5%
ROE 87.4% 54.5% 81.1% 206.9% 35.9% 82.1% 25.3% 43.1% 59.4% 3.8% 24.8% -19.2%
ROIC without Goodwill 162.8% 260.0% 354.8% 89.7% -3.8% 66.8% -1.2% 136.5% 50.2% 58.7% 33.0% -37.9%
ROIC with Goodwill 162.8% 260.0% 354.8% 89.7% -3.8% 66.8% -1.2% 136.5% 50.2% 58.7% 24.2% -30.5%
RONIC without Goodwill -58.2% 611.9% 13.1% -301.3% -310.8% 103.1% -231.5% 158.2% 57.8% 26.7% -178.5%
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2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Revenues 22,661.5 22,597.8 23,015.4 23,467.6 24,266.1 24,562.8 24,863.1 25,167.1 25,474.8 25,786.3 
Operating expenses 11,547.5 11,344.7 11,503.9 11,957.0 12,356.6 12,827.8 12,999.0 13,172.4 13,347.9 13,525.5 
      % of Revenues 51.0% 50.2% 50.0% 51.0% 50.9% 52.2% 52.3% 52.3% 52.4% 52.5%
  Cost of Sales 4,102.4   4,090.8   4,166.4   4,248.3   4,392.8   4,446.5   4,500.9   4,555.9   4,611.6   4,668.0   
      % of Revenues 18.1% 18.1% 18.1% 18.1% 18.1% 18.1% 18.1% 18.1% 18.1% 18.1%
      (-) Depreciation and Amortization 1,742.1-   1,885.6-   1,884.8-   1,690.0-   1,695.8-   1,487.7-   1,491.4-   1,495.2-   1,499.1-   1,503.0-   
  Research and Development (R&D) 4,075.2   4,041.8   4,030.4   4,104.9   4,185.5   4,327.9   4,380.9   4,434.4   4,488.6   4,543.5   
      % of Revenues 0.2          17.8% 17.8% 17.8% 17.8% 17.8% 17.8% 17.8% 17.8% 17.8%
  Selling, general and administrative 4,830.0   4,816.5   4,905.5   5,001.9   5,172.0   5,235.3   5,299.3   5,364.1   5,429.7   5,496.0   
      % of Revenues 21.3% 21.3% 21.3% 21.3% 21.3% 21.3% 21.3% 21.3% 21.3% 21.3%
  Other operating expenses 282.0      281.2      286.4      292.1      302.0      305.7      309.4      313.2      317.0      320.9      
      % of Revenues 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%
EBITDA 11,114.0 11,253.1 11,511.4 11,510.6 11,909.5 11,735.0 11,864.1 11,994.7 12,126.9 12,260.7 
      % of Revenues 49.0% 49.8% 50.0% 49.0% 49.1% 47.8% 47.7% 47.7% 47.6% 47.5%
Depreciation 589.4       591.0       590.7       592.4       594.3       597.5       598.7       599.9       601.2       602.4       
Amortization 1,152.8     1,294.6     1,294.0     1,097.6     1,101.5     890.2       892.7       895.3       897.9       900.5       
EBIT 9,371.9   9,367.5   9,626.7   9,820.6   10,213.7 10,247.3 10,372.6 10,499.5 10,627.8 10,757.8 
      % of Revenues 41.4% 41.5% 41.8% 41.8% 42.1% 41.7% 41.7% 41.7% 41.7% 41.7%
Operating cash taxes 3,618.3     3,663.6     3,747.7     3,747.4     3,877.3     3,820.5     3,862.5     3,905.0     3,948.0     3,991.6     
NOPLAT 5,753.6   5,704.0   5,879.0   6,073.2   6,336.4   6,426.9   6,510.2   6,594.5   6,679.8   6,766.2   
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11.16. Amgen’s NOPLAT Forecast Drivers 
 
 





2015 2016 2017 Forecast Driver 2018 2019
Revenues 21,662.0 22,991.0 22,849.0 22,661.5 22,597.8 
Operating Expenses 11,065.4 11,078.6 10,921.5 11,616.2 11,413.5 
      % of Revenues 51.1% 48.2% 47.8% 51.3% 50.5%
  Cost of Sales 4,227.0     4,162.0     4,069.0     4,102.4     4,090.8     
      % of Revenues 19.5% 18.1% 17.8% 18.1% 18.1% 18.1%
  Research and Development (R&D) 4,070.0     3,840.0     3,562.0     4,075.2     4,041.8     
      % of Revenues 20.3% 17.7% 15.5% 17.8% 17.8% 17.8%
  Selling, General and Administrative 4,846.0     5,062.0     4,870.0     4,830.0     4,816.5     
      % of Revenues 22.4% 22.0% 21.3% 21.3% 21.3% 21.3%
  Other Operating Expenses 49.0         133.0       375.0       282.0       281.2       
      % of Revenues 0.2% 0.6% 1.6% 1.2% 1.2% 1.2%
NET INCOME - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
NOPLAT 5,753.6   5,704.0   5,879.0   6,073.2   6,336.4   6,426.9   6,510.2   6,594.5   6,679.8   6,766.2   
Interest expense, net -1,332.1 -1,262.6 -1,259.1 -1,282.4 -1,307.6 -1,352.0 -1,368.6 -1,385.3 -1,402.3 -1,419.4
Interest and other income, net 990.3 772.1 855.1 916.7 922.1 938.1 942.9 955.4 971.0 983.4
Non-operating income -16.0 -16.0 -16.3 -16.6 -17.2 -17.4 -17.6 -17.8 -18.0 -18.3
Nonoperating taxes -120.7 -173.2 -142.6 -129.1 -136.1 -146.1 -150.3 -56.8 -56.8 -56.8
Net Income 5,275.1   5,024.2   5,316.1   5,561.8   5,797.8   5,849.5   5,916.6   6,089.9   6,173.7   6,255.1   
Net Income Margin 23.3% 22.2% 23.1% 23.7% 23.9% 23.8% 23.8% 24.2% 24.2% 24.3%
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INVESTED CAPITAL - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Operating Current Assets 8,504.5      8,480.6      8,637.3      8,807.0     9,106.6     9,218.0     9,330.7      9,444.8      9,560.3      9,677.2      
(-) Operating Current Liabilities 6,507.4 6,489.1 6,609.0 6,738.8 6,968.1 7,053.3 7,139.6 7,226.8 7,315.2 7,404.7
Total Operating Working Capital 1,997.1 1,991.5 2,028.3 2,068.2 2,138.5 2,164.7 2,191.1 2,217.9 2,245.1 2,272.5
(+) Net Property, Plant and Equipment 5,094.9 5,197.1 5,312.5 5,440.0 5,590.2 5,746.3 5,910.3 6,082.5 6,262.9 6,451.5
(+) Other Operating Assets, net of Other Liabilities 498.6 497.2 506.3 516.3 533.9 540.4 547.0 553.7 560.4 567.3
(+) Net Intangible Assets 8,980.4 9,205.7 9,459.6 9,940.4 10,470.9 11,232.8 12,012.3 12,809.7 13,625.2 14,459.0
Invested Capital (Excluding Goodwill) 16,570.9 16,891.5 17,306.8 17,964.9 18,733.6 19,684.2 20,660.8 21,663.8 22,693.6 23,750.3
(+) Goodwill 14,761.0 14,761.0 14,761.0 14,761.0 14,761.0 14,761.0 14,761.0 14,761.0 14,761.0 14,761.0
Invested Capital (Including Goodwill) 31,331.9 31,652.5 32,067.8 32,725.9 33,494.6 34,445.2 35,421.8 36,424.8 37,454.6 38,511.3
(+) Excess Cash 211.7 3,925.7 5,997.4 5,567.2 5,085.0 4,854.6 4,957.9 5,189.2 5,277.0 5,291.4
(+) Excess Marketable Securities 33,468.9 33,374.8 33,991.5 34,659.4   35,838.7   36,276.8   36,720.4    37,169.4    37,623.8    38,083.9    
(+) Other Non Operating Assets, net of Other Non 
Operating Liabilities 356.0 356.0 356.0 356.0       356.0       356.0       356.0        356.0        356.0        356.0        
Total Funds Invested 65,368.5 69,308.9 72,412.6 73,308.5 74,774.2 75,932.6 77,456.1 79,139.4 80,711.5 82,242.6
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EQUITY AND DEBT - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Equity
  Common stock and additional paid-in capital 30,992.0  30,992.0  30,992.0  30,992.0   30,992.0   30,992.0   30,992.0    30,992.0    30,992.0    30,992.0    
  Accumulated deficit 5,072.0-    5,072.0-    5,072.0-    5,072.0-   5,072.0-   5,072.0-   5,072.0-    5,072.0-    5,072.0-    5,072.0-    
  Foreign Currency Translation Reserve 458.8-       397.8-       345.0-       299.2-      259.5-      225.0-      195.1-       169.2-       146.8-       127.3-       
  Cash Flow Hedges 119.7       119.7       119.7       119.7      119.7      119.7      119.7       119.7       119.7       119.7       
  Available for Sale Securities 144.0-       144.0-       144.0-       144.0-      144.0-      144.0-      144.0-       144.0-       144.0-       144.0-       
  Retained Earnings 1,911.0    6,723.5    8,113.9    7,678.3   7,908.8   8,673.3   9,735.3    10,867.4  11,851.9  12,830.1  
    Starting Retained Earnings (beg. of period) -          1,911.0    6,723.5    8,113.9   7,678.3   7,908.8   8,673.3    9,735.3    10,867.4  11,851.9  
    Net income 5,275.1    5,024.2    5,316.1    5,561.8   5,797.8   5,849.5   5,916.6    6,089.9    6,173.7    6,255.1    
    Dividends 3,364.1      211.7        3,925.7      5,997.4   5,567.2   5,085.0   4,854.6    4,957.9    5,189.2    5,277.0    
    Ending Retained Earnings (end of period) 1,911.0    6,723.5    8,113.9    7,678.3   7,908.8   8,673.3   9,735.3    10,867.4  11,851.9  12,830.1  
Deferred tax liabilities, net of deferred tax assets 3,637.5    3,627.2    3,694.3    3,767 3,895 3,943 3,991 4,040 4,089 4,139
Dividends payable 884.2       55.7         1,031.8    1,576.4     1,463.3     1,336.6     1,276.0      1,303.1      1,363.9      1,387.0      
Adjusted Equity 31,869.7  35,904.3  38,390.7  38,618.0 38,903.4 39,623.2 40,702.8  41,936.7  43,053.9  44,124.6  
Debt 
Short-term Debt 2,099.5 2,093.6 2,132.3 2,174.2 2,248.1 2,275.6 2,303.4 2,331.6 2,360.1 2,389.0
Long-term Debt 31,399.4 31,311.1 31,889.7 32,516.3 33,622.7 34,033.8 34,449.9 34,871.1 35,297.5 35,729.1
New Issue Debt 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Total Debt 33,498.9 33,404.7 34,022.0 34,690.5 35,870.8 36,309.4 36,753.3 37,202.7 37,657.6 38,118.0
Total Funds Invested 65,368.5 69,308.9 72,412.6 73,308.5 74,774.2 75,932.6 77,456.1 79,139.4 80,711.5 82,242.6
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FREE CASH-FLOW STATEMENT - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 Continuing Value
NOPLAT 5,753.6 5,704.0 5,879.0 6,073.2 6,336.4 6,426.9 6,510.2 6,594.5 6,679.8 6,766.2
(+) Depreciation 589.4     591.0     590.7     592.4     594.3     597.5     598.7     599.9     601.2     602.4     
(+) Amortization 1,152.8  1,294.6  1,294.0  1,097.6  1,101.5  890.2     892.7     895.3     897.9     900.5     
Gross Cash-Flow 7,495.7 7,589.5 7,763.8 7,763.2 8,032.2 7,914.6 8,001.6 8,089.7 8,178.9 8,269.1
Investment in Operating Working Capital 815.2     5.6-        36.8       39.9       70.4       26.1       26.5       26.8       27.1       27.5       
Capital Expenditures 695.2     693.3     706.1     720.0     744.5     753.6     762.8     772.1     781.5     791.1     
Investment in Other Operating Assets, net 
of Other Liabilities 11.4-       1.4-        9.2        9.9        17.6       6.5        6.6        6.7        6.8        6.9        
Investment in Intangible Assets 1,524.2  1,519.9  1,548.0  1,578.4  1,632.1  1,652.0  1,672.2  1,692.7  1,713.4  1,734.3  
Investment in Goodwill -        -        -        -        -        -        -        -        -        -        
Gross Investment 3,023.2 2,206.1 2,300.0 2,348.1 2,464.5 2,438.3 2,468.1 2,498.3 2,528.8 2,559.7 
Free Cash-Flow 4,472.6 5,383.4 5,463.7 5,415.1 5,567.7 5,476.3 5,533.5 5,591.4 5,650.1 5,709.4 84,222.3
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11.21. Amgen’s Sensitivity Analysis 
 
11.22. Amgen’s Multiples 
 
SENSITIVITY ANALYSIS - $M
Valuation Scenario Scenario 1 Scenario 2
WACC 8.1% 7.1% 9.1%
Valuation 120,020.8              136,942.4 108,165.3   
Impact on Valuation -                         16,921.6   11,855.6-     
Growth rate in Perpetuity 1.1% 0.5% 2.1%
Valuation 120,020.8              119,994.3 120,084.91 
Impact on Valuation -                         26.6-          64.1            
Average Revenues growth rate 1.2% 3.4% -0.8%
Valuation 120,020.8              165,703.4 95,580.7     
Impact on Valuation -                         45,682.6   24,440.1-     
Operating Expenses (% of Revenues) 51.5% 41.5% 61.5%
Valuation 120,020.8              159,642.6 88,242.2     
Impact on Valuation -                         39,621.8   31,778.6-     
R&D Expenses (% of Revenues) 17.8% 15.5% 20.4%
Valuation 120,020.8              128,205.8 111,058.7   
Impact on Valuation -                         8,185.0     8,962.2-       
MULTIPLES - $M
EV/EBITDA EV/EBIT EV/Revenues
AbbVie (x) 14.8 16.5 6.3
Gilead Sciences (x) 6.8 7.2 4.1
Average 10.8 11.8 5.2
Amgen's EBITDA 11,928.0     
Amgen's EBIT 9,973.0       
Amgen's Revenues 22,849.0     
Amgen's Enterprise Value 128,822.4   117,930.7   118,472.1    
Amgen's Equity Value 130,767.71 119,876.04 120,417.38  
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2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenues 1,783.0 2,030.9 2,340.3 2,630.0  3,018.2  3,454.9  3,954.8  4,527.1  5,182.1  5,931.9  6,370.8  6,842.3 7,348.6 7,892.4 8,476.4 
Operating Expenses 1,493.7 1,712.1 1,968.5 2,242.3  2,554.7  2,791.0  3,199.2  3,666.5  4,201.4  4,813.6  
      % of Revenues 83.8% 84.3% 84.1% 85.3% 84.6% 80.8% 80.9% 81.0% 81.1% 81.1%
Cost of Sales 67.3      76.7      88.4      99.3       114.0     130.4     149.3     170.9     195.7     224.0     
      % of Revenues 3.8% 3.8% 3.8% 3.8% 3.8% 3.8% 3.8% 3.8% 3.8% 3.8%
      (-) Depreciation and Amortization 59.1-      71.7-      76.3-      82.0-       87.3-       85.8-       93.9-       103.1-     113.6-     125.7-     
  Research and Development (R&D) 697.6    809.7    922.3    1,062.8  1,194.3  1,219.7  1,396.2  1,598.2  1,829.4  2,094.1  
      % of Revenues 45.4% 45.4% 45.4% 45.4% 45.4% 40.4% 40.4% 40.4% 40.4% 40.4%
  Selling, general and administrative 760.5    866.2    998.2    1,121.7  1,287.3  1,473.6  1,686.8  1,930.8  2,210.2  2,530.0  
      % of Revenues 42.7% 42.7% 42.7% 42.7% 42.7% 42.7% 42.7% 42.7% 42.7% 42.7%
  Other operating expenses 27.4      31.2      36.0      40.4       46.4       53.1       60.8       69.6       79.7       91.2       
      % of Revenues 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%
EBITDA 289.2    318.8    371.8    387.7     463.5     663.9     755.6     860.6     980.7     1,118.2  
      % of Revenues 16.2% 15.7% 15.9% 14.7% 15.4% 19.2% 19.1% 19.0% 18.9% 18.9%
Depreciation 38.5       37.6       40.4       43.9        47.2        51.6        56.6        62.3        68.8        76.2        
Amortization 20.5       34.1       35.8       38.0        40.1        34.2        37.3        40.8        44.8        49.4        
EBIT 230.2    247.1    295.5    305.8     376.2     578.1     661.8     757.5     867.1     992.6     
      % of Revenues 12.9% 12.2% 12.6% 11.6% 12.5% 16.7% 16.7% 16.7% 16.7% 16.7%
Operating cash taxes 5.0         5.5         6.5         6.7          8.1          11.5        13.1        15.0        17.0        19.4        
NOPLAT 225.2    241.6    289.1    299.1     368.2     566.6     648.6     742.6     850.1     973.1     1,045.1  1,122.5 1,205.6 1,294.8 1,390.6 
      % of Revenues 12.6% 11.9% 12.4% 11.4% 12.2% 16.4% 16.4% 16.4% 16.4% 16.4% 16.4% 16.4% 16.4% 16.4% 16.4%
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11.24. Incyte’s NOPLAT Forecast Drivers 
 
 







2015 2016 2017 Forecast Driver 2018 2019
Revenues 753.8    1,105.7 1,536.2 1,783.0 2,030.9 
Operating expenses 691.8    934.0    1,733.9 1,500.2 1,719.5 
      % of Revenues 91.8% 84.5% 112.9% 84.1% 84.7%
  Cost of Sales 27.0       45.6       58.0       67.3       76.7       
      % of Revenues 3.6% 4.1% 3.8% 3.8% 3.8% 3.8%
  Research and Development (R&D) 330.4     384.2     1,037.6  697.6     809.7     
      % of Revenues 64.6% 51.0% 93.8% 45.4% 45.4% 45.4%
  Selling, general and administrative 345.7     501.0     655.2     760.5     866.2     
      % of Revenues 45.9% 45.3% 42.7% 42.7% 42.7% 42.7%
  Other operating expenses -        30.0       29.2       33.9       38.6       
      % of Revenues 0.0% 2.7% 1.9% 1.5% 1.9% 1.9%
NET INCOME - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
NOPLAT 225.2    241.6    289.1    299.1     368.2     566.6     648.6     742.6     850.1     973.1     1,045.1  1,122.5 1,205.6 1,294.8 1,390.6 
Interest expense, net -1.1 -1.3 -1.5 -1.7 -1.9 -2.2 -2.5 -2.9 -3.3 -3.8 -4.3 -4.7 -5.0 -5.4 -5.8
Interest and other income, net 15.4 13.7 13.6 13.6 13.1 12.8 14.2 15.7 17.4 19.2 21.3 22.8 25.3 28.1 31.0
Net Income 239.5    254.0    301.2    310.9     379.4     577.2     660.3     755.4     864.1     988.6     1,062.1  1,140.6 1,225.9 1,317.5 1,415.8 
Net Income Margin 12.3% 11.5% 11.8% 10.7% 11.2% 16.8% 16.9% 16.9% 16.9% 16.9% 16.9% 17.0% 17.0% 17.0% 17.0%
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INVESTED CAPITAL - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
OPERATING WORKING CAPITAL
Operating Current Assets 388.9      443.0      510.5      573.7      658.4      753.6      862.6      987.5      1,130.3    1,293.9    1,389.6    1,492.5    1,602.9     1,721.5     1,848.9      
(-) Operating Current Liabilities 387.9      441.9      509.2      572.2      656.7      751.7      860.5      985.0      1,127.5    1,290.7    1,386.2    1,488.8    1,598.9     1,717.2     1,844.3      
Total Operating Working Capital 1.0 1.1 1.3 1.4 1.6 1.9 2.1 2.5 2.8 3.2 3.5 3.7 4.0 4.3 4.6
(+) Net Property, Plant and Equipment 356.3      472.5      609.4      764.7      946.0      1,156.1    1,399.0    1,679.6    2,003.3    2,376.4    2,774.2    3,202.7    3,664.2     4,161.1     4,696.0      
(+) Other Operating Assets, net of Other Liabilities 81.4        92.7        106.8      120.1      137.8      157.7      180.5      206.7      236.6      270.8      290.8      312.3      335.5       360.3       386.9        
(+) Net Intangible Assets 363.9      497.7      655.5      835.0      1,044.5    1,296.1    1,585.9    1,919.6    2,303.4    2,744.6    3,216.8    3,724.9    4,271.6     4,859.6     5,492.2      
Invested Capital (Excluding Goodwill) 802.5 1,064.1 1,372.9 1,721.1 2,130.0 2,611.8 3,167.7 3,808.3 4,546.1 5,395.0 6,285.2 7,243.6 8,275.2 9,385.3 10,579.8
(+) Goodwill 155.6      155.6      155.6      155.6      155.6      155.6      155.6      155.6      155.6      155.6      155.6      155.6      155.6       155.6       155.6        
Invested Capital (Including Goodwill) 958.1 1,219.7 1,528.5 1,876.7 2,285.6 2,767.4 3,323.3 3,963.9 4,701.7 5,550.6 6,440.8 7,399.2 8,430.8 9,540.9 10,735.4
(+) Excess Cash 672.6      622.3      561.3      474.0      377.6      397.7      415.9      431.9      445.3      455.7      482.8      583.7      690.7       804.3       924.9        
(+) Excess Marketable Securities 335.3      382.0      440.2      494.7      567.7      649.8      743.8      851.4      974.6      1,115.7    1,198.2    1,286.9    1,382.1     1,484.4     1,594.2      
(+) Other Non Operating Assets, net of Other Non 
Operating Liabilities 68.2-        68.2-        68.2-        68.2-        68.2-        68.2-        68.2-        68.2-        68.2-        68.2-        0.9          0.9          0.9           0.9           0.9            
Total Funds Invested 1,897.9 2,155.7 2,461.8 2,777.2 3,162.7 3,746.7 4,414.8 5,179.1 6,053.5 7,053.8 8,122.7 9,270.7 10,504.5 11,830.5 13,255.4
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11.27. Incyte’s Equity and Debt Forecast 
 
 
11.28. Incyte’s Free Cash Flow Forecast 
 
EQUITY AND DEBT - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Equity
  Common stock 0.2         0.2         0.2         0.2         0.2         0.2         0.2         0.2         0.2         0.2         0.2         0.2         0.2          0.2          0.2           
  Additional paid-in capital 3,627.4  3,627.4  3,627.4  3,627.4  3,627.4  3,627.4  3,627.4  3,627.4  3,627.4  3,627.4  3,627.4  3,627.4  3,627.4   3,627.4   3,627.4    
  Accumulated deficit 1,990.0-  1,990.0-  1,990.0-  1,990.0-  1,990.0-  1,990.0-  1,990.0-  1,990.0-  1,990.0-  1,990.0-  1,990.0-  1,990.0-  1,990.0-   1,990.0-   1,990.0-    
  Accumulated other comprehensive loss 7.0-         7.0-         7.0-         7.0-         7.0-         7.0-         7.0-         7.0-         7.0-         7.0-         7.0-         7.0-         7.0-          7.0-          7.0-           
  Retained Earnings 239.5     493.4     794.6     1,105.5  1,484.9  2,062.1  2,722.4  3,477.8  4,341.9  5,330.5  6,392.6  7,533.2  8,759.1   10,076.6 11,492.4  
    Starting Retained Earnings (beg. of period) -        239.5     493.4     794.6     1,105.5  1,484.9  2,062.1  2,722.4  3,477.8  4,341.9  5,330.5  6,392.6  7,533.2   8,759.1   10,076.6  
    Net income 239.5     254.0     301.2     310.9     379.4     577.2     660.3     755.4     864.1     988.6     1,062.1  1,140.6  1,225.9   1,317.5   1,415.8    
    Ending Retained Earnings (end of period) 239.5     493.4     794.6     1,105.5  1,484.9  2,062.1  2,722.4  3,477.8  4,341.9  5,330.5  6,392.6  7,533.2  8,759.1   10,076.6 11,492.4  
Adjusted Equity 1,870.1  2,124.0  2,425.2  2,736.1  3,115.5  3,692.7  4,353.0  5,108.4  5,972.5  6,961.1  8,023.2  9,163.8  10,389.7 11,707.2 13,123.0  
Debt 
Short-term Debt 8.6 9.8 11.3 12.7 14.5 16.6 19.1 21.8 25.0 28.6 30.7 33.0 35.4 38.0 40.8
Long-term Debt 19.3 21.9 25.3 28.4 32.6 37.3 42.7 48.9 56.0 64.1 68.8 73.9 79.4 85.3 91.6
New Issued Debt -         -         -         -         -         -         -         -         -         -         -         -         -          -          -           
Total Debt 27.9 31.7 36.6 41.1 47.2 54.0 61.8 70.7 81.0 92.7 99.5 106.9 114.8 123.3 132.4
Total Funds Invested 1,897.9 2,155.7 2,461.8 2,777.2 3,162.7 3,746.7 4,414.8 5,179.1 6,053.5 7,053.8 8,122.7 9,270.7 10,504.5 11,830.5 13,255.4
FREE CASH-FLOW STATEMENT -$M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 Continuing Value
NOPLAT 225.2 241.6 289.1 299.1 368.2 566.6 648.6 742.6 850.1 973.1 1,045.1 1,122.5 1,205.6 1,294.8 1,390.6
(+) Depreciation 38.5       37.6       40.4       43.9       47.2       51.6       56.6       62.3       68.8       76.2       84.7       89.7       95.1       100.8     107.0     
(+) Amortization 20.5       34.1       35.8       38.0       40.1       34.2       37.3       40.8       44.8       49.4       54.7       57.8       61.1       64.7       68.5       
Gross Cash-Flow 284.2 313.3 365.3 381.0 455.5 652.4 742.5 845.6 963.7 1,098.8 1,184.6 1,270.0 1,361.8 1,460.3 1,566.1
Investment in Operating Working Capital 23.8-       0.1        0.2        0.2        0.2        0.2        0.3        0.3        0.4        0.4        0.2        0.3        0.3        0.3        0.3        
Capital Expenditures 135.0     153.8     177.3     199.2     228.6     261.7     299.5     342.9     392.5     449.3     482.5     518.2     556.6     597.8     642.0     
Investment in Other Operating Assets, net of 
Other Liabilities 43.4-       11.3       14.1       13.2       17.7       19.9       22.8       26.1       29.9       34.2       20.0       21.5       23.1       24.8       26.7       
Investment in Intangible Assets 147.5     168.0     193.6     217.5     249.6     285.8     327.1     374.4     428.6     490.6     526.9     565.9     607.8     652.8     701.1     
Investment in Goodwill -        -        -        -        -        -        -        -        -        -        -        -        -        -        -        
Gross Investment 215.3    333.3    385.1    430.1    496.2    567.6    649.7    743.7    851.4    974.5    1,029.7 1,105.9 1,187.8 1,275.7 1,370.1 
Free Cash-Flow 68.9 -20.0 -19.8 -49.1 -40.7 84.8 92.8 101.9 112.3 124.3 154.9 164.1 174.0 184.7 196.1 17,299.8
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11.29. Incyte’s Sensitivity Analysis 
 
11.30. Incyte’s Multiples 
 
SENSITIVITY ANALYSIS - $M
Valuation Scenario Scenario 1 Scenario 2
WACC 8.2% 7.2% 9.2%
Valuation 17,854.5                  34,338.9    11,832.7    
Impact on Valuation -                          16,484.4    6,021.8-      
Growth rate in Perpetuity 6.2% 3.8% 7.4%
Valuation 17,854.5                  18,577.1    15,753.0    
Impact on Valuation -                          722.6        2,101.5-      
Average Revenues growth rate 7.4% 14.5% 3.8%
Valuation 17,854.5                  7,299.1-      7,203.0      
Impact on Valuation -                          25,153.6-    10,651.5-    
Operating Expenses (% of Revenues) 82.7% 52.4% 97.2%
Valuation 17,854.5                  327,602.3  252,291.3-  
Impact on Valuation -                          309,747.7  270,145.9-  
R&D Expenses (% of Revenues) 42.9% 19.8% 93.8%
Valuation 17,854.5                  251,519.2  547,417.1-  
Impact on Valuation -                                  233,664.6  565,271.7-  
MULTIPLES - $M
EV/EBITDA EV/EBIT EV/Revenues
Vertex Pharmaceuticals (x) 83.8 96.9 15.3
Alexion Pharmaceuticals (x) 20.2 33.3 7.2
Repligen Corporation (x) 63.7 111.5 11.1
Average 55.9 80.6 11.2
Incyte's EBITDA (2016) 171.7          
Incyte's EBIT (2016) 144.9          
Incyte's Revenues (2016) 1,536.2       
Incyte's Enterprise Value 9,596.9       11,674.1     17,159.4     
Incyte's Equity Value 10,682.16   12,759.39   18,244.63   
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11.31. Combined Firm’s NOPLAT 
 
11.32. Combined Firm’s Net Income 
 
NOPLAT - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Revenues 24,444.5 24,628.7 25,355.7 26,097.6 27,284.3 28,017.7 28,817.9 29,694.2 30,656.9 31,718.2 
Operating Expenses 13,113.2 13,129.6 13,546.4 14,274.3 14,987.8 15,627.7 16,199.0 16,830.3 17,529.9 18,307.6 
      % of Revenues 53.6% 53.3% 53.4% 54.7% 54.9% 55.8% 56.2% 56.7% 57.2% 57.7%
  Cost of Sales 4,169.7     4,167.5     4,254.8     4,347.6     4,506.8     4,577.0     4,650.2     4,726.9     4,807.3     4,892.0     
      (-) Depreciation and Amortization 1,735.7-     1,891.8-     1,895.5-     1,706.5-     1,717.5-     1,508.0-     1,519.8-     1,532.8-     1,547.2-     1,563.1-     
  Research and Development (R&D) 4,772.8     4,851.4     4,952.6     5,167.6     5,379.8     5,547.6     5,777.0     6,032.6     6,318.1     6,637.6     
  Selling, general and administrative 5,590.5     5,682.7     5,903.6     6,123.6     6,459.3     6,639.7     6,907.0     7,204.4     7,536.2     7,907.4     
  Other operating expenses 315.9       319.8       330.9       342.0       359.4       371.4       384.6       399.3       415.5       433.7       
EBITDA 11,331.3 11,499.1 11,809.2 11,823.3 12,296.5 12,390.0 12,618.9 12,863.9 13,127.0 13,410.6 
      % of Revenues 46.4% 46.7% 46.6% 45.3% 45.1% 44.2% 43.8% 43.3% 42.8% 42.3%
Depreciation 562.4       563.1       565.6       570.8       576.0       583.6       589.8       596.7       604.4       613.1       
Amortization 1,173.3     1,328.7     1,329.9     1,135.6     1,141.6     924.4       930.0       936.1       942.7       950.0       
EBIT 9,595.6   9,607.3   9,913.7   10,116.8 10,579.0 10,882.0 11,099.2 11,331.1 11,579.8 11,847.5 
      % of Revenues 39.3% 39.0% 39.1% 38.8% 38.8% 38.8% 38.5% 38.2% 37.8% 37.4%
Operating cash taxes 3,617.4     3,664.7     3,752.6     3,753.4     3,888.6     3,851.1     3,900.4     3,951.2     4,003.6     4,058.0     
NOPLAT 5,978.2   5,942.6   6,161.2   6,363.4   6,690.4   7,030.9   7,198.8   7,379.9   7,576.2   7,789.5   
NET INCOME - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
NOPLAT 5,978.2   5,942.6   6,161.2   6,363.4   6,690.4   7,030.9   7,198.8   7,379.9   7,576.2   7,789.5   
Interest expense, net 1,333.2-     1,263.9-     1,260.6-     1,288.1-     1,319.0-     1,370.1-     1,385.8-     1,401.7-     1,417.9-     1,434.3-     
Interest and other income, net 1,007.8     788.5       871.2       933.0       938.6       954.6       959.3       971.8       987.4       999.9       
Non-operating income 16.0-         16.0-         16.3-         16.6-         17.2-         17.4-         17.6-         17.8-         18.0-         18.3-         
Nonoperating taxes 120.7-       173.5-       143.1-       129.5-       136.4-       146.5-       150.7-       56.8-         56.8-         56.8-         
Net Income 5,516.1   5,277.6   5,612.4   5,862.3   6,156.4   6,451.4   6,604.0   6,875.4   7,070.8   7,279.9   
Net Income Margin 22.6% 21.4% 22.1% 22.5% 22.6% 23.0% 22.9% 23.2% 23.1% 23.0%
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INVESTED CAPITAL - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Operating Current Assets 8,893.4     8,923.6     9,147.8     9,380.7     9,765.0      9,971.6      10,193.4    10,432.3    10,690.6    10,971.0    
(-) Operating Current Liabilities 6,895.3     6,930.9     7,118.2     7,311.1     7,624.8      7,805.0      8,000.1      8,211.9      8,442.7      8,695.3      
Total Operating Working Capital 1,998.1   1,992.6   2,029.6   2,069.6   2,140.2    2,166.6    2,193.3    2,220.4    2,247.9    2,275.7    
(+) Net Property, Plant and Equipment 5,519.9     5,807.3     6,128.3     6,480.0     6,880.5      7,315.7      7,791.8      8,313.7      8,887.0      9,518.0      
(+) Other Operating Assets, net of Other Liabilities 579.9       589.9       613.2       636.3       671.6        698.1        727.5        760.3        797.0        838.1        
(+) Net Intangible Assets 9,344.2     9,703.4     10,115.1   10,775.3   11,515.5    12,528.9    13,598.3    14,729.3    15,928.6    17,203.6    
Invested Capital (Excluding Goodwill) 17,442.2 18,093.2 18,886.1 19,961.3 21,207.8  22,709.3  24,310.9  26,023.8  27,860.5  29,835.4  
(+) Goodwill 14,916.6   14,916.6   14,916.6   14,916.6   14,916.6    14,916.6    14,916.6    14,916.6    14,916.6    14,916.6    
Invested Capital (Including Goodwill) 32,358.8 33,009.8 33,802.7 34,877.9 36,124.4  37,625.9  39,227.5  40,940.4  42,777.1  44,752.0  
(+) Excess Cash 838.0       4,487.9     6,506.8     5,995.4     5,416.2      5,204.1      5,325.2      5,573.2      5,674.7      5,699.4      
(+) Excess Marketable Securities 33,804.2   33,756.7   34,431.6   35,154.1   36,406.3    36,926.7    37,464.2    38,020.8    38,598.5    39,199.5    
(+) Other Non Operating Assets, net of Other 
Non Operating Liabilities 287.8       287.8       287.8       287.8       287.8        287.8        287.8        287.8        287.8        287.8        
Total Funds Invested 67,288.8 71,542.2 75,029.0 76,315.1 78,234.8  80,044.4  82,304.7  84,822.2  87,338.1  89,938.7  
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EQUITY AND DEBT - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Equity
  Common stock and paid-in capital 0.2          0.2          0.2          0.2          0.2           0.2           0.2           0.2           0.2           0.2           
  Additional Paid-In Capital 34,619.4 34,619.4 34,619.4 34,619.4 34,619.4  34,619.4  34,619.4  34,619.4  34,619.4  34,619.4  
  Accumulated deficit 7,062.0-   7,062.0-   7,062.0-   7,062.0-   7,062.0-    7,062.0-    7,062.0-    7,062.0-    7,062.0-    7,062.0-    
  Accumulated other comprehensive income 
(loss) 7.0-          7.0-          7.0-          7.0-          7.0-           7.0-           7.0-           7.0-           7.0-           7.0-           
  Foreign Currency Translation Reserve 458.8-      397.8-      345.0-      299.2-      259.5-       225.0-       195.1-       169.2-       146.8-       127.3-       
  Cash Flow Hedges 119.7      119.7      119.7      119.7      119.7       119.7       119.7       119.7       119.7       119.7       
  Available for Sale Securities 144.0-      144.0-      144.0-      144.0-      144.0-       144.0-       144.0-       144.0-       144.0-       144.0-       
  Retained Earnings 2,172.9   7,306.7   9,078.8   9,026.8   9,703.7    11,112.8  12,904.3  14,861.7  16,779.6  18,815.4  
(+) Deferred tax liabilities, net of deferred tax 
assets 3,637.5   3,627.2   3,694.3   3,766.9   3,895.0    3,942.6    3,990.8    4,039.6    4,089.0    4,139.0    
(+) Dividends payable 884.2      43.5        1,016.1   1,562.7   1,451.2    1,324.4    1,263.3    1,290.4    1,351.3    1,374.5    
Adjusted Equity 33,762.1 38,105.8 40,970.4 41,583.5 42,316.8  43,681.1  45,489.6  47,548.8  49,599.6  51,728.0  
Debt 
Short-term Debt 2,099.8     2,093.9     2,132.6     2,174.5     2,248.4      2,275.9      2,303.7      2,331.9      2,360.4      2,389.3      
Long-term Debt 31,400.1   31,311.8   31,890.4   32,517.0   33,623.4    34,034.5    34,450.6    34,871.8    35,298.2    35,729.7    
New Issue Debt -           -           -           -           -           -           -           -           -           -           
Total Debt 33,499.9 33,405.7 34,023.0 34,691.5 35,871.8  36,310.4  36,754.3  37,203.7  37,658.6  38,119.0  
Total Funds Invested 67,262.0 71,511.5 74,993.4 76,275.0 78,188.6  79,991.5  82,243.9  84,752.5  87,258.2  89,847.0  
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11.35. Combined Firm’s Free Cash-Flow Statement 
 
 
11.36. Combined Firm’s Potential Synergies 
 
FREE CASH-FLOW STATEMENT -$M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
NOPLAT 5,978.2   5,942.6   6,161.2   6,363.4   6,690.4   7,030.9   7,198.8   7,379.9   7,576.2   7,789.5   
(+) Depreciation 562.4      563.1      565.6      570.8      576.0      583.6      589.8      596.7      604.4      613.1      
(+) Amortization 1,173.3   1,328.7   1,329.9   1,135.6   1,141.6   924.4      930.0      936.1      942.7      950.0      
Gross Cash-Flow 7,713.9  7,834.3  8,056.7  8,069.9  8,407.9  8,538.9  8,718.6  8,912.7  9,123.3  9,352.6  
Investment in Operating Working Capital 791.5      5.5-         37.0       40.0       70.6       26.4       26.7       27.1       27.5       27.9       
Capital Expenditures 830.3      847.1      883.3      919.2      973.1      1,015.2   1,062.3   1,115.0   1,174.0   1,240.4   
Investment in Other Operating Assets, net 
of Other Liabilities 54.9-       9.9         23.3       23.2       35.3       26.5       29.4       32.8       36.7       41.1       
Investment in Intangible Assets 1,671.6   1,687.9   1,741.5   1,795.9   1,881.7   1,937.8   1,999.3   2,067.1   2,142.0   2,225.0   
Investment in Goodwill -         -         -         -         -         -         -         -         -         -         
Gross Investment 3,238.5  2,539.4  2,685.1  2,778.2  2,960.6  3,005.9  3,117.8  3,242.0  3,380.2  3,534.3  
Free Cash-Flow 4,475.4  5,295.0  5,371.5  5,291.7  5,447.3  5,533.0  5,600.7  5,670.7  5,743.2  5,818.3  
SYNERGIES 
Revenues Enhancements
Stronger position in Europe Revenues increase by 0.5%
Knowledge transfer Revenues represent 142.3% of increase in R&D expenditures
Increase in investing power in R&D Increase in R&D Expenditures for 35% of previous year's Revenues
Cost Savings
Decrease in number of Administrative, Sales and Marketing employees Decrease of employees by 50%
Stronger position over suppliers Cost of Sales decrease by 3.5%
Close of facility in Switzerland Decrease in Net PPE in 11.6
Manufacture of own products instead of contracting with 3rd parties Decrease of Incyte's SG&A costs with 3rd parties by 30%
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11.37. Combined Firm’s NOPLAT after Synergies 
 
11.38. Combined Firm’s Net Income after Synergies 
 
NOPLAT - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Revenues 24,444.5 24,628.7  25,355.7 26,097.6 27,284.3 28,017.7 28,817.9 29,694.2 30,656.9 31,718.2 
  Synergies effects -         -          -         130.5      136.4      5,414.8   5,551.3   5,910.9   3,826.1   3,800.9   
Operating Expenses 13,041.2 45,990.9  15,264.0 16,890.4 17,625.9 18,574.0 17,457.8 17,964.8 18,502.0 18,565.6 
  Cost of Sales 4,169.7     4,167.5      4,254.8     4,347.6     4,506.8     4,577.0     4,650.2     4,726.9     4,807.3     4,892.0     
  Synergies effects -         -          -         152.2-      157.7-      160.2-      162.8-      165.4-      168.3-      171.2-      
      (-) Depreciation and Amortization 1,801.2-   1,888.4-    1,892.2-   1,701.6-   1,717.5-   1,507.9-   1,655.8-   1,672.2-   1,719.0-   1,693.7-   
  Research and Development (R&D) 4,772.8     4,851.4      4,952.6     5,167.6     5,379.8     5,547.6     5,777.0     6,032.6     6,318.1     6,637.6     
  Synergies effects -         -          -         3,706.9   3,800.0   4,049.6   2,581.1   2,559.7   2,583.2   1,983.1   
  Selling, general and administrative 5,590.5     5,682.7      5,903.6     6,123.6     6,459.3     6,708.8     6,986.0     7,294.9     7,639.9     8,026.0     
  Synergies effects 873.7-       888.7-      933.5-      992.0-      1,064.1-   1,153.1-   1,262.3-   1,395.6-   1,557.9-   
  Other operating expenses 309.4       312.5        322.4       332.0       347.1       423.2       435.1       450.7       436.5       449.6       
  Synergies effects -         33,739.0  2,611.4   -         -         -         -         -         -         -         
EBITDA 11,403.3 21,362.2-  10,091.7 9,337.7   9,794.8   14,858.4 16,911.4 17,640.2 15,980.9 16,953.5 
Depreciation 627.9       559.7        562.3       565.9       573.7       581.3       634.5       642.6       676.7       679.2       
Amortization 1,173.3     1,328.7      1,329.9     1,135.6     1,143.8     926.6       1,021.2     1,029.6     1,042.3     1,014.5     
EBIT 9,602.1   23,250.6-  8,199.5   7,636.1   8,077.4   13,350.5 15,255.6 15,968.0 14,261.9 15,259.8 
Operating cash taxes 3,623.3     6,787.7-      3,206.6     2,967.0     3,112.2     4,721.2     5,373.5     5,605.1     5,077.8     5,386.9     
NOPLAT 5,978.8   16,462.9-  4,992.9   4,669.1   4,965.1   8,629.3   9,882.1   10,362.9 9,184.1   9,872.9   
NET INCOME - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
NOPLAT 5,978.8   16,462.9-  4,992.9   4,669.1   4,965.1   8,629.3   9,882.1   10,362.9 9,184.1   9,872.9   
Interest expense, net 1,333.2-     1,262.9-      1,531.2-     1,433.1-     1,355.0-     1,333.5-     1,328.1-     1,306.7-     1,286.8-     1,259.7-     
Interest and other income, net 1,007.8     406.8        409.9       422.0       436.5       456.3       556.4       572.0       592.5       573.9       
Non-operating income 16.0-         16.0-          16.3-         16.6-         17.2-         17.4-         17.6-         17.8-         18.0-         18.3-         
Nonoperating taxes 120.7-       305.6-        400.3-       361.0-       327.9-       313.2-       275.5-       262.3-       247.9-       244.9-       
Net Income 5,516.6   17,640.7-  3,455.0   3,280.4   3,701.5   7,421.6   8,817.3   9,348.0   8,223.9   8,923.9   
Net Income Margin 22.6% -71.6% 13.6% 12.5% 13.5% 22.2% 25.7% 26.3% 23.8% 25.1%
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INVESTED CAPITAL - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Operating Current Assets 8,893.4      8,923.6      9,147.8      9,380.7      9,765.0      9,971.6      10,193.4    10,432.3    10,690.6     10,971.0     
  Synergies effects -          -          -          107.3       111.3       218.6       223.0       232.1       192.3        193.9        
(-) Operating Current Liabilities 6,895.3      6,930.9      7,118.2      7,311.1      7,624.8      7,805.0      8,000.1      8,211.9      8,442.7       8,695.3       
  Synergies effects 711.8-       731.1-       762.5-       780.5-       800.0-       821.2-       844.3-        869.5-        
Total operating working capital 1,998.1    1,992.6    2,741.4    2,908.0    3,013.9    3,165.6    3,216.3    3,273.7    3,284.5     3,339.1     
Net Property, Plant and Equipment (NPPE) 5,519.9      5,807.3      6,116.7      6,478.8      6,887.5      7,689.6      8,494.9      9,545.5      10,574.7     11,525.1     
(+) Other Operating Assets, net of Other Liabilities 579.9        584.3        601.6        622.3        650.6        793.2        815.4        844.7        818.1         842.7         
(+) Net Intangible Assets 9,344.2      9,703.4      10,115.1    10,793.1    11,551.8    13,301.6    15,126.0    17,060.9    18,780.5     20,572.4     
Invested Capital (Excluding Goodwill) 17,442.2  18,087.6  19,574.8  20,802.2  22,103.7  24,950.0  27,652.6  30,724.8  33,457.8   36,279.3   
(+) Goodwill 22,038.6    22,038.6    22,038.6    22,038.6    22,038.6    22,038.6    22,038.6    22,038.6    22,038.6     22,038.6     
Invested Capital (Including Goodwill) 39,480.9  40,126.3  41,613.4  42,840.8  44,142.4  46,988.7  49,691.2  52,763.4  55,496.4   58,318.0   
(+) Excess Cash 12,074.9    -           -           98.0          1,231.7      1,831.4      4,975.1      5,071.1      5,612.6       5,022.3       
(+) Excess Marketable Securities 15,398.1    15,514.1    15,972.0    16,521.6    17,272.9    21,059.8    21,649.9    22,428.3    21,721.5     22,374.2     
(+) Other non Operating Assets, net of Other non 
Operating Liabilities 287.8        287.8        287.8        287.8        287.8        287.8        287.8        287.8        287.8         287.8         
Total Funds Invested 67,241.7  55,928.2  57,873.3  59,748.3  62,934.7  70,167.6  76,604.0  80,550.6  83,118.4   86,002.2   
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EQUITY AND DEBT - $M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Equity
  Common stock and paid-in capital 0.2           0.2           0.2           0.2           0.2           0.2           0.2           0.2           0.2            0.2            
  Additional Paid-In Capital 34,619.4  34,619.4  34,619.4  34,619.4  34,619.4  34,619.4  34,619.4  34,619.4  34,619.4   34,619.4   
  Accumulated deficit 7,062.0-    7,062.0-    7,062.0-    7,062.0-    7,062.0-    7,062.0-    7,062.0-    7,062.0-    7,062.0-     7,062.0-     
  Accumulated other comprehensive income 
(loss) 7.0-           7.0-           7.0-           7.0-           7.0-           7.0-           7.0-           7.0-           7.0-            7.0-            
  Foreign Currency Translation Reserve 458.8-       397.8-       345.0-       299.2-       259.5-       225.0-       195.1-       169.2-       146.8-        127.3-        
  Cash Flow Hedges 119.7       119.7       119.7       119.7       119.7       119.7       119.7       119.7       119.7        119.7        
  Available for Sale Securities 144.0-       144.0-       144.0-       144.0-       144.0-       144.0-       144.0-       144.0-       144.0-        144.0-        
  Retained Earnings 2,152.5    15,488.1-  12,033.1-  8,752.7-    5,051.3-    2,370.4    9,356.3    13,729.3  16,882.1   20,193.4   
    Starting Retained Earnings -          2,152.5    15,488.1-  12,033.1-  8,752.7-    5,051.3-    2,370.4    9,356.3    13,729.3   16,882.1   
    Net Income 5,516.6    17,640.7-  3,455.0    3,280.4    3,701.5    7,421.6    8,817.3    9,348.0    8,223.9     8,923.9     
    Dividends 3,364.1    -          -          -          -          -          1,831.4    4,975.1    5,071.1     5,612.6     
    Ending Retained Earnings 2,152.5    15,488.1-  12,033.1-  8,752.7-    5,051.3-    2,370.4    9,356.3    13,729.3  16,882.1   20,193.4   
(+) Deferred tax liabilities, net of deferred tax 
assets 3,637.5    3,627.2    3,694.3    3,766.9    3,895.0    3,942.6    3,990.8    4,039.6    4,089.0     4,139.0     
(+) Dividends payable 884.2       43.5         1,016.1    1,562.7    1,451.2    1,324.4    1,263.3    1,290.4    1,351.3     1,374.5     
Adjusted Equity 33,741.8  15,311.1  19,858.5  23,804.0  27,561.8  34,938.7  41,941.7  46,416.4  49,702.0   53,106.0   
Debt 
Short-term Debt 2,099.8      2,115.6      2,178.1      2,253.0      2,355.4      2,871.8      2,952.3      3,058.5      2,962.1       3,051.1       
Long-term Debt 31,400.1    31,636.7    32,570.6    33,691.3    33,017.5    32,357.1    31,710.0    31,075.8    30,454.3     29,845.2     
New Issue Debt -           6,864.8      3,266.1      -           -           -           -           -           -            -            
Total Debt 33,499.9  40,617.1  38,014.8  35,944.3  35,372.9  35,229.0  34,662.3  34,134.2  33,416.3   32,896.3   
Total Funds Invested 67,241.7  55,928.2  57,873.3  59,748.3  62,934.7  70,167.6  76,604.0  80,550.6  83,118.4   86,002.2   
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FREE CASH-FLOW STATEMENT -$M
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 Continuing Value
NOPLAT 5,978.8     16,462.9-   4,992.9   4,669.1   4,965.1   8,629.3     9,882.1     10,362.9   9,184.1     9,872.9     
(+) Depreciation 627.9       559.7       562.3     565.9     573.7     581.3       634.5       642.6       676.7       679.2       
(+) Amortization 1,173.3     1,328.7     1,329.9   1,135.6   1,143.8   926.6       1,021.2     1,029.6     1,042.3     1,014.5     
Gross Cash-Flow 7,779.9   14,574.5- 6,885.1 6,370.7 6,682.6 10,137.3 11,537.9 12,035.1 10,903.1 11,566.6 
Investment in operating working capital 791.5       5.5-           748.8     166.6     105.9     151.7       50.7         57.3         10.8         54.7         
Net Capital Expenditures 830.3       847.1       871.8     928.0     982.3     1,383.4     1,439.8     1,693.2     1,705.9     1,629.6     
Investment in other operating assets, net of 
other liabilities 54.9-         4.4           17.2       20.7       28.3       142.6       22.2         29.3         26.6-         24.6         
Investment in intangible assets 1,671.6     1,687.9     1,741.5   1,813.7   1,900.3   2,674.2     2,754.3     2,871.0     2,662.3     2,741.9     
Investment in goodwill 7,122.0     -          -        -        -        -          -          -          -          -          
Gross Investment 10,360.6 2,533.8   3,379.3 2,929.0 3,016.8 4,351.9   4,267.1   4,650.9   4,352.4   4,450.8   
Free Cash-Flow 2,580.6-   17,108.3- 3,505.8 3,441.7 3,665.8 5,785.3   7,270.8   7,384.3   6,550.6   7,115.9   156,427.4          
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Combined Firm without Synergies Combined Firm with Synergies
Revenues Average Growth Rate
R&D Expenses (Average % of Revenues)
Average EBITDA Margin
Average EBITDA Margin (excl. 2019 and 2020)
Average Net Income Margin
Average Net Income Margin (excl. 2019 and 2020) 21.3%
Free Cash-Flow Average Growth Rate
Average EBITDA/Interest Expense 
Average EBITDA/Interest Expense (excl. 2019 and 2020) 11.0
Average Debt/EBITDA
Average Debt/EBITDA (excl. 2019 and 2020) 2.5
Average Debt/Total Funds Invested
Average Debt/Total Funds Invested (excl. 2019 and 2020) 47.5%
Average ROE 3.4%
Average ROE (excl. 2019 and 2020) 20.8%
Average ROIC without Goodwill
Average ROIC without Goodwill (excl. 2019 and 2020)
Average RONIC without Goodwill
































11.43. Synergies’ Sensitivity Analysis 
SENSITIVITY ANALYSIS - $M
Valuation Scenario Scenario 1 Scenario 2
Stronger position in Europe 0.5% 0.0% 3.8%
Value of Synergies 28,522.8             25,072.8     49,789.4     
Impact on Value of Synergies -                      3,450.0-       21,266.6     
Revenues regarding R&D expenditures 142.3% 100.0% 166.3%
Value of Synergies 28,522.8             24,416.5     31,074.9     
Impact on Value of Synergies -                      4,106.3-       2,552.1       
Increased market power over suppliers -3.5% -2.0% -5.0%
Value of Synergies 28,522.8             27,537.2     29,508.7     
Impact on Value of Synergies -                      985.6-          985.9          
Decrease in administrative employees -50.0% -40.0% 60.0%
Value of Synergies 28,522.8             29,955.9     27,089.9     
Impact on Value of Synergies -                      1,433.2       1,432.9-       
Decrease in SG&A Expenses 30.0% 40.0% 20.0%
Value of Synergies 28,522.8             34,676.8     21,967.9     
Impact on Value of Synergies -                      6,154.0       6,554.8-       
Increased R&D Expenditure 35.0% 40.0% 30.0%
Value of Synergies 28,522.8             25,457.9     22,635.8     
Impact on Value of Synergies -                      3,064.9-       5,887.0-       
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